

Skin and Tissue Substitutes



Medicaid Medical Coverage Policy

Original Effective Date: 01/01/2025

Effective Date: 07/01/2025

Review Date: 02/04/2025

Policy Number: HUM-2208-001

Line of Business: Medicaid

State: VA

Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Appendix](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Description

Bioengineered skin and soft tissue substitutes, often referred to as cellular and/or tissue-based products (CTPs), are acellular (no biological component) or cellular (contain living cells) matrices. Acellular dermal matrices (ADM) or extracellular matrices (ECM) have had all cellular material removed during the manufacturing process and contain a matrix or scaffold composed of materials such as collagen, elastin, fibronectin and hyaluronic acid. These products vary in several ways including source (biological tissue, synthetic materials or a combination), additives (antibiotics, surfactants), hydration (freeze dried, wet) and required preparation (multiple rinses, rehydration).

Cellular matrices contain living cells such as fibroblasts and keratinocytes within a matrix which are derived from either autologous or allogeneic (human tissue) or xenographic (animal tissue), synthetic materials or a composite of these materials.

Manufacturing processes of bioengineered skin and tissue substitutes vary by company, but generally involve seeding selected cells onto a matrix, where they receive proteins and growth factors necessary for them to multiply and develop into the desired tissue. The tissue may be used for a variety of conditions and procedures including breast reconstruction, healing of lower extremity ulcers (eg, diabetic and/or venous ulcers), ocular defects, plantar fasciitis, surgical wounds and treatment of severe burns.

Coverage Determination

Humana members may be eligible under the Plan for **skin and tissue substitutes** when the following criteria are met:

Skin / Tissue Substitute	Indication(s) / Criteria	Associated HCPCS Code(s)
<u>AlloDerm Select RTM</u> Processed from human cadaver skin with the cells responsible for immune response and graft rejection removed. The remainder is a matrix or framework of natural biological components, ready to enable the body to mount its own tissue regeneration process.	For use in association with a covered, medically necessary breast reconstruction procedure	Q4116
<u>Apligraf</u> Much like human skin as it has two primary layers; the epidermal (outer) layer consists of live human keratinocytes, while the dermal (inner) layer contains living fibroblasts. Also referred to as human skin equivalent.	- Use with standard therapeutic compression for the treatment of noninfected partial- and full-thickness skin ulcers due to venous insufficiency of greater than 4 weeks duration and have not adequately responded to standard wound therapy; OR - Individual with type 1 or type 2 diabetes mellitus, who have full-thickness, neuropathic diabetic foot ulcers of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure	Q4101
<u>Biobrane, Biobrane-L</u> Constructed using collagen (porcine type 1) that is incorporated with both silicone and nylon and mechanically bonded to a flexible knitted nylon fabric.	- Full-thickness (third-degree) burns; OR - Partial-thickness (second-degree) burns	Q4100
<u>Cortiva and Cortiva 1 mm Allograft Dermis</u> Non-crosslinked acellular dermal matrix.	For use in association with a covered, medically necessary breast reconstruction procedure	Q4100
<u>DermACELL</u> Acellular human dermis.	For use in association with a covered, medically necessary breast reconstruction procedure	Q4122
<u>Dermagraft</u> Manufactured from human fibroblast cells derived from newborn foreskin	Full-thickness, neuropathic diabetic ulcers of the plantar surface of the foot, of greater than 4 weeks duration that have not	Q4106

Skin / Tissue Substitute	Indication(s) / Criteria	Associated HCPCS Code(s)
tissue. The fibroblasts are cultured on a bioabsorbable polyglactin mesh. Proteins and growth factors are secreted during the culture period and generate a three dimensional (3D) human dermis.	adequately responded to standard wound therapy , where there is no bone, capsule, muscle or tendon exposure; AND Used in conjunction with standard wound therapy	
<u>Epifix</u> Biologic human amniotic membrane.	- Full-thickness diabetic foot ulcers greater than 4 weeks duration that extend through the dermis, but without bone, capsule, muscle or tendon exposure; AND - Used in conjunction with standard wound therapy	Q4186
<u>FlexHD</u> Human allograft skin minimally processed to remove epidermal and dermal cells and preserve the ECM of the dermis.	For use in association with a covered, medically necessary breast reconstruction procedure (excluding implant-based breast reconstruction)	Q4128
<u>Grafix Core, Grafix Prime</u> ECM containing growth factors.	Treatment of partial- and full-thickness neuropathic diabetic foot ulcers that are greater than 4 weeks in duration, with no bone, capsule or tendon exposed, when used in conjunction with standard wound therapy	Q4132, Q4133
<u>GraftJacket Regenerative Tissue Matrix</u> Derived from cadaveric skin, which undergoes a process that removes the epidermis and dermal cells. The human dermal tissue is preserved. Over time, the body's natural repair process converts the matrix into living tissue.	- Full-thickness diabetic foot ulcers greater than 4 weeks duration that extend through the dermis, but without bone, capsule, muscle or tendon exposure; AND - Used in conjunction with standard wound therapy	Q4107
<u>Integra Bilayer Matrix Wound Dressing</u> Comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan and a semipermeable polysiloxane (silicone layer). The collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth.	- Treatment of chronic venous or diabetic partial- and full-thickness ulcers, of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure; OR - Partial-thickness (second-degree) burns	Q4104
<u>Integra Dermal Regeneration Template, Omnigraft</u>	Postexcisional treatment of life-threatening, full-thickness or deep partial-thickness thermal injuries where sufficient autograft is	Q4105

Skin / Tissue Substitute	Indication(s) / Criteria	Associated HCPCS Code(s)
Bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer.	not available at the time of excision or not desirable due to the physiological condition of the individual; OR • Repair of scar contractures when other therapies have failed or when donor sites for repair are not sufficient or desirable due to the physiological condition of the individual; OR • Treatment of partial- and full-thickness neuropathic diabetic foot ulcers that are greater than 4 weeks in duration, with no bone, capsule or tendon exposed, when used in conjunction with standard wound therapy	
<u>Integra Meshed Bilayer Wound Matrix</u> Porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan. The collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth. The meshed bilayer matrix allows drainage of wound exudate and provides a flexible adherent covering for the wound surface.	• Treatment of chronic venous or diabetic partial- and full-thickness ulcers, of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure; OR • Partial-thickness (second-degree) burns	Q4104, C9363
<u>Oasis Ultra Tri-Layer Matrix, Oasis Wound Matrix</u> A naturally derived, ECM created from the submucosal layer of porcine small intestine.	• Treatment of difficult to heal chronic venous or diabetic partial- and full-thickness ulcers of the lower extremity that have failed standard wound therapy of at least 4 weeks duration	Q4124, Q4102
<u>Transcyte</u> Combines a synthetic epidermis with a bioengineered human dermal layer that contains fibronectin growth factors and collagen	• For use as a temporary wound covering for surgically excised full-thickness and deep partial-thickness thermal burn wounds in an individual who requires such a covering prior to autograft placement; OR • Treatment of mid-dermal to indeterminate depth burn wounds that typically require debridement and that may be expected to heal without autografting	Q4182

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for any of the following **skin and tissue substitutes** for **ANY** other indication or when the above criteria are not met including, but may not be limited to:

- AlloDerm Select RTM; **OR**
- Apligraf; **OR**
- Biobrane, Biobrane-L; **OR**
- Cortiva and Cortiva 1 mm Allograft Dermis; **OR**
- DermACELL; **OR**
- Dermagraft; **OR**
- Epifix; **OR**
- FlexHD; **OR**
- Grafix Core, Grafix Prime; **OR**
- GraftJacket Regenerative Tissue Matrix; **OR**
- Integra Bilayer Matrix Wound Dressing; **OR**
- Integra Dermal Regeneration Template, Omnigraft (Integra DRT); **OR**
- Integra Meshed Bilayer Wound Matrix; **OR**
- Oasis Ultra-Tri-Layer Matrix; **OR**
- Oasis Wound Matrix; **OR**
- Transcyte

These are considered experimental/investigational as they are not identified as widely used and generally accepted for any other proposed uses as reported in nationally recognized peer-reviewed medical literature published in the English language.

Humana members may **NOT** be eligible under the Plan for any of the following **skin and tissue substitutes** for **ANY** indication:

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
AC5 Advanced Wound System Lyophilized peptide in sterile water for injection. Biocompatible and resorbable peptides that self-assemble into a nanofiber network which resembles the construct of the extracellular matrix.	• Topical dressing for the management of wounds including: ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers	A2020

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Venous ulcers	
<u>ACApatch</u> Dehydrated human amniotic membrane allograft composed of three-layers: two amnion layers and one chorion layer.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4325
<u>Acesso</u> Dehydrated single layer human amniotic membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4311
<u>Acesso AC</u> Dehydrated dual layer human amniotic/chorion membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4312
<u>Acesso DL</u> Dehydrated dual layer human amniotic membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4293
<u>Acesso TL</u> Dehydrated triple layer human amniotic membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4300
<u>ACTISHIELD, ACTISHIELD CF</u> Allografts derived from dehydrated human amniotic tissue.	• Homologous use to cover and protect tissue	Q4100
<u>Activate Matrix</u> Triple layer human amnion and chorionic membrane allograft.	• Wound covering or barrier membrane	Q4301
<u>ActiveBarrier, ActiveMatrix, CryoMatrix</u> Placental connective tissue matrix.	• Surgical use to supplement or replace damaged or inadequate connective tissue	Q4100
<u>Affinity</u> Minimally processed amniotic fluid membrane allograft.	• Onlay graft for: ○ Acute and chronic wounds including neuropathic ulcers, pressure ulcers and venous stasis ulcers ○ Burns ○ Postsurgical wounds ○ Posttraumatic wounds	Q4159
<u>Allogen Liquid</u>	• Burns	Q4212

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Human liquid amnion.	Chronic, nonhealing wounds	
<u>AlloMax</u> A sterile regenerative human collagen matrix.	- Soft tissue repair including: - Breast reconstruction - Chest wall defect - Hernia repair	Q4100
<u>Allopatch HD</u> Acellular human dermis derived from human allograft skin that is processed to preserve and maintain the natural biomechanical, biochemical and matrix properties of the dermal graft.	Provision of ECM scaffold for tendon augmentation	Q4128
<u>alloPLY</u> Dual layer human amniotic epithelium/basement membrane allograft.	Wound covering or barrier membrane	Q4323
<u>AlloSkin, AlloSkin AC, AlloSkin RT</u> Allograft derived from epidermal and dermal cadaveric tissue.	Acute and chronic wound therapy	Q4115, Q4141, Q4123
<u>Allowrap DS or dry</u> Double-sided epithelial layer human amniotic membrane.	Onlay and/or wrapping tissue applications following surgical repair	Q4150
<u>AltiPly, AMNIOREPAIR</u> Lyophilized placental membrane allografts.	Acute and chronic wound therapy	Q4235
<u>AmchoPlast</u> Human amniotic/chorion membrane allograft.	Wound covering or barrier membrane	Q4316
<u>American Amnion</u> Decellularized human amniotic allograft.	Protective barrier or covering for acute and chronic wounds including partial and full thickness wounds	Q4307
<u>American Amnion AC</u> Decellularized human amniotic and chorionic allograft.	Protective barrier or covering for acute and chronic wounds including partial and full thickness wounds	Q4306
<u>American Amnion AC Tri-Layer</u> Decellularized human amniotic, intermediate and chorionic allograft.	Protective barrier or covering for acute and chronic wounds including partial and full thickness wounds	Q4305
<u>Amnio Quad-Core</u> Four-layer human amniotic membrane allograft.	Wound covering or barrier membrane	Q4294
<u>Amnio Tri-Core</u>	Wound covering or barrier membrane	Q4295

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Triple layer human amniotic membrane allograft.		
<u>Amnio Wound</u> Lyophilized human amniotic membrane allograft comprised of an epithelial layer and two fibrous connective tissue layers specifically processed to be used for the repair and replacement of lost or damaged dermal tissue.	• Intended for the following conditions: ○ Adhesion barrier ○ Burn wounds ○ Diabetic ulcers ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pre- and post-surgical wounds ○ Pressure injuries ○ Scar tissue ○ Venous stasis ulcers	Q4181
<u>Amnio-Maxx</u> Dual layered, dehydrated, amniotic tissue membrane graft. <u>Amnio-Maxx Lite</u> Single layer, dehydrated, amniotic tissue membrane graft.	• Chronic wound covering for: ○ Diabetic ulcers ○ Soft tissue defects ○ Venous stasis ulcers	Q4239
<u>AmnioAMP-MP</u> Decellularized dehydrated human amniotic membrane (DDHAM) which is derived from the placental amnion.	• Partial- or full-thickness skin wounds such as: ○ Burns ○ Diabetic ulcers ○ Pressure ulcers ○ Venous ulcers • Repair of skin over any wound including those with exposed bone, muscle or tendon	Q4250
<u>Amnioarmor</u> Dehydrated human amniotic membrane allograft derived from the submucosa of placental tissue.	• Acute and chronic wound therapy	Q4188
<u>Amnioband or Guardian – Membrane, Particulate</u> Human tissue allografts made of donated placental membranes.	• Soft tissue defects • Surgical sites • Ulcers • Wounds	Q4151, Q4168
<u>AmnioBind or DermaBind TL</u> Dehydrated, full-thickness placental membrane (PM) allograft consisting of	• Acute and chronic wound therapy	Q4225

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
amnion, chorion, and the associated intermediate (spongy) layer (IL).		
<u>AmnioCord</u> Dehydrated human umbilical cord allograft.	- Connective tissue matrix to replace or supplement damaged or inadequate integumental tissue - Surgical wrap or barrier	Q4100
<u>AmnioCore</u> Dual layer amniotic tissue allograft.	Acute and chronic wound therapy	Q4227
<u>AmnioCore Pro</u> Dual layer human amnion and chorionic membrane allograft.	Wound covering or barrier membrane	Q4298
<u>AmnioCore Pro+</u> Triple layer human amnion and chorionic membrane allograft.	Wound covering or barrier membrane	Q4299
<u>AmnioCyte Plus</u> Minimally manipulated human tissue allograft derived from the extracellular matrix of the amniotic membrane.	Replace or supplement damaged or inadequate tissue	Q4242
<u>AmnioExcel, AmnioExcel Plus or BioDExcel</u> Amniotic extracellular membrane is a sterile, resorbable, noncross-linked tissue allograft derived from the human amnion.	Scaffold for tissue repair and regeneration	Q4137
<u>AmnioFill</u> Cellular tissue matrix allograft that contains multiple ECM proteins, growth factors, cytokines, and other specialty proteins.	- Modulate inflammation in the surgical site - Reduce scar tissue formation - Replace or supplement damaged or inadequate integumental tissue for acute and chronic wounds	Q4100
<u>AmnioFix</u> Human amniotic membrane comprises the innermost layer of the placenta and lines the amniotic cavity.	- Modulate inflammation in the surgical site - Reduce scar tissue formation - Surgical wrap or barrier	Q4100
<u>AmnioFLEX, ASG Barrier, ASG Fluid</u> Human tissue, chorion free allograft, comprised of minimally manipulated	- Aid in the healing and repair of wounds - Construct a natural scaffold for new tissue growth	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
amniotic membrane derived from placental tissue.		
<u>AmnioGraft</u> Minimally manipulated, cryopreserved amniotic membrane.	Any indication other than ocular use (eg, diabetic ulcer)	Q4100
<u>AmnioHeal Plus</u> Amniotic membrane graft	- Chronic wound covering for: - Burns - Diabetic ulcers - Pressure ulcers - Venous stasis ulcers	Q4100
<u>AmnioMatrix, BioDMatrix</u> Cryopreserved (frozen) complex of amniotic tissue, liquid human allograft.	- Anti-inflammatory wound dressing - Hollow regions of bone - Soft tissue injuries	Q4139
<u>Amnion Bio, AxoBioMembrane</u> Human amnion allograft.	- Acute and chronic wounds - Partial- or full-thickness skin wounds	Q4211
<u>AmnioPlast 1</u> Monolayered human amnion membrane allograft.	Covering or barrier applied to the ocular surface	Q4334
<u>AmnioPlast 2</u> Human amnion chorion membrane allograft.	Covering or barrier applied to the ocular surface	Q4335
<u>Amniotext</u> Minimally manipulated, amniotic membrane derived human tissue allograft.	Provides a barrier and support function to aid in healing of defect	Q4245
<u>Amniotext patch</u> Minimally manipulated amniotic membrane derived human tissue allograft.	- Management of chronic wounds including: - Diabetic foot ulcers - Venous ulcers	Q4247
<u>AmnioTX</u> Dehydrated dual layer human amniotic membrane allograft.	Wound covering or barrier membrane	Q4324
<u>AmnioWrap2</u> Amniotic/chorionic tissue allograft.	- Management of wounds including: - Acute and chronic wounds - Chronic vascular ulcers - Diabetic ulcers - Venous ulcers	Q4221
<u>Amniplay</u>	Chronic wound covering for:	Q4249

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
Collagenous membrane derived from the submucosa of the placenta.	○ Diabetic foot ulcers ○ Pressure ulcers ○ Venous leg ulcers	
<u>Apis</u> Biodegradable and absorbable gelatin, a porcine collagen derivative, is the primary material. The two other materials are Manuka honey and hydroxyapatite.	● Management of wounds including: ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, healing by secondary intention) ○ Venous ulcers	A2010
<u>Architect, Architect PX, Architect FX ECM</u> Stabilized collagen matrix.	● Partial- or full-thickness skin wounds such as: ○ Diabetic foot ulcers ○ Second-degree burns ○ Venous leg ulcers	Q4147
<u>ArdeoGraft</u> Dual layer human chorionic membrane allograft.	● Wound covering or barrier membrane, over acute and chronic wounds	Q4333
<u>Artacent AC</u> Human amnion/chorion membrane graft.	● Acute and chronic wounds such as: ○ Burns ○ Diabetic ulcers ○ Pressure ulcers ○ Venous stasis ulcers ○ Wounds that are refractory to more conservative care	Q4189, Q4190
<u>Artacent C</u> Single layer human amnion chorion membrane allograft.	● Wound covering for acute and chronic wounds	Q4336

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Artacent Cord</u> Umbilical cord allograft.	• Acute and chronic wounds such as: ○ Burns ○ Diabetic ulcers ○ Venous stasis ulcers ○ Wounds that are refractory to more conservative care	Q4216
<u>Artacent Wound</u> Amniotic tissue graft with an epithelial layer of native membrane facing out on both sides.	• Surgical barrier for these types of surgeries: ○ Extremity ○ Orthopedic ○ Plastics ○ Spinal ○ Urological ○ Vascular	Q4169
<u>Artacent Trident</u> Triple layer human amnion membrane allograft.	• Wound covering for acute and chronic wounds	Q4337
<u>Artacent Velos</u> Dual layer human amnion membrane allograft.	• Wound covering for acute and chronic wounds	Q4338
<u>Artacent Vericlen</u> Human amnion-chorion membrane allograft.	• Wound covering for acute and chronic wounds	Q4339
<u>ArthroFlex</u> Decellularized dermis patch.	• Achilles tendon repair and shoulder reconstruction	Q4125
<u>Ascent</u> Dehydrated cell and protein concentrate (dCPC) injectable derived from human amniotic fluid.	• Burns • Chronic, nonhealing wounds	Q4213
<u>Avance Nerve Graft</u> Processed, decellularized nerve allograft.	• Alternative to nerve conduits for nerve repair procedures	Q4100
<u>Axograft</u> Dual layer amniotic membrane.	• Promote bone healing, spinal fusion and wound treatment in spinal arthrodesis procedures	Q4100
<u>Axolotl Ambient, Axolotl Cryo</u> Human amniotic flowable allografts.	• Soft tissue injuries	Q4215
<u>Axolotl DualGraft</u>	• Wound covering or barrier membrane	Q4332

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
Human amniotic membrane allograft.		
<u>Axolotl Graft</u> Human amniotic membrane allograft.	• Wound covering or barrier membrane	Q4331
<u>Barrera SL, Barrera DL</u> Dehydrated human amniotic membrane allograft.	• Barrier or cover for wounds including surgically created wounds	Q4281
<u>BellaCell HD</u> Human acellular dehydrated dermis regenerative tissue matrix.	• Abdominal wall and hiatal hernia repair • Breast reconstruction • Burns • Skin ulcers	Q4220
<u>Bio-ConneKt</u> Conformable and porous wound dressing made of reconstituted collagen derived from equine tendon.	• Management of moderately to heavily exuding wounds including: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grfts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Venous ulcers	Q4161
<u>BioDFactor</u> Flowable tissue allografts derived from human amniotic tissue and components of amniotic fluid.	• Wound covering in the treatment of localized tissue defects or areas of inflammation	Q4100
<u>BioDFence</u> Hydrated human amniotic membrane allograft.	• Repair or replacement of lost or damaged dermal tissue	Q4140

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
<u>BioDFence DryFlex</u> Dehydrated human amnionic membrane allograft.	Repair or replacement of lost or damaged dermal tissue	Q4138
<u>BioFix, BioFix Plus, BioFix Flow</u> Amniotic allografts derived from human placental tissue.	- Wound covering for: - Surgical sites - Tissue defects - Tissue voids	Q4100
<u>BioSkin, WoundEx</u> Human ECM placental tissue allografts.	Wounds and soft tissue defects	Q4163
<u>BioSkin Flow, WoundEx Flow</u> Human ECM placental tissue injectable allografts.	Wounds and soft tissue defects	Q4162
<u>Biovance</u> Dehydrated, decellularized human amniotic membrane.	Treatment or replacement of damaged or lost soft tissue	Q4154
<u>Biovance Tri-layer, Biovance 3L</u> Triple-layer decellularized, dehydrated human amniotic membrane.	Cover or protect, from the surrounding environment, in wound, surgical repair and reconstruction procedures	Q4283
<u>BioWound, BioWound Plus, BioWound XPlus, WoundFix, WoundFix Plus, WoundFix XPlus</u> Human amnion-based membranes.	- Repair of acute and chronic wounds including, but may not be limited to: - Burns - Chronic vascular ulcers - Diabetic ulcers - Partial- and full-thickness wounds - Pressure ulcers - Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) - Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) - Venous ulcers	Q4217

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	Repair of skin over any wound including those with exposed bone, capsule, muscle or tendon	
<u>CaregraFT</u> Dehydrated human amniotic/chorion membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4322
<u>carePATCH</u> Dehydrated amniotic membrane allograft.	Barrier or cover for wounds including surgically created wounds	Q4236
<u>Celera Dual Membrane, Celera Dual Layer</u> Amniotic and/or chorionic allograft derived from placental tissue.	Wound covering or barrier membrane	Q4259
<u>Cellesta, Cellesta Duo</u> Minimally manipulated amniotic membrane allograft.	- Acute, chronic and surgically created wound therapy - Burns - Urologic and gynecological surgeries	Q4184
<u>Cellesta Cord</u> Umbilical cord allograft product.	- Acute and chronic wound therapy - Surgical wounds	Q4214
<u>Cellesta Flowable Amnion</u> Minimally manipulated, chorion-free human amniotic membrane.	Application in difficult to access wound sites, deep dermal wounds, irregularly shaped crevassing and tunneling wounds	Q4185
<u>Cocoon Membrane</u> Human amnionic membrane allograft.	- Acute and chronic wounds - Partial- or full-thickness skin wounds	Q4264
<u>Cogenex Amniotic Membrane</u> Minimally manipulated, amniotic membrane allograft.	- Burns - Chronic, nonhealing wounds - Urologic and gynecological surgeries	Q4229
<u>Cogenex Flowable Amnion</u> Minimally manipulated, amniotic membrane allograft.	Application in difficult to access wound sites, deep dermal wounds, irregularly shaped crevassing and tunneling wounds	Q4230
<u>Coll-e-derm</u> Allograft derived from human dermal tissue.	Regenerative support to wounds and burns	Q4193
<u>Complete AA</u> Dual layer human amnion membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4303

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Complete ACA</u> Triple layer human amnion and chorionic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4302
<u>Complete FT</u> Resorbable full-thickness amnion/chorion allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4271
<u>Complete SL</u> Resorbable single layer amniotic allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4270
<u>CoreCyte</u> Wharton's jelly allograft.	Aid in the healing and repair of wounds	Q4240
<u>CoreText, ProText</u> Wharton's jelly allograft.	- Cartilage tears - Muscle tears - Soft tissue defects - Wounds	Q4246
<u>Corplex</u> Human umbilical cord allograft composed of the epithelial layer and the Wharton's jelly.	Acute and chronic wound therapy	Q4232
<u>Corplex P</u> Wharton's jelly allograft.	Wound covering for connective tissue voids	Q4231
<u>Cryo-Cord</u> Minimally manipulated umbilical cord allograft.	Chronic, nonhealing wounds	Q4237
<u>Cygnus Dual</u> Amniotic tissue matrix.	Barrier or cover for wounds	Q4282
<u>Cygnus Matrix</u> Amniotic tissue matrix.	- Burn care - Dermatology - Foot and ankle surgery - Oral surgery - Reconstructive surgery - Spine and neurosurgery - Urology - Wound care	Q4199
<u>Cygnus (Cryopreserved Max, Max, Max XL, Matrix, Solo)</u> Amniotic tissue allograft.	Soft tissue barrier or wound covering	Q4170
<u>Cymetra</u> Micronized particulate form of AlloDerm processed from human cadaver skin.	Correction of soft tissue defects requiring minimally invasive techniques	Q4112

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Cytal Wound Matrix</u> (formerly MatriStem Wound Matrix and Multilayer Wound Matrix) Porcine derived ECM scaffold containing epithelial basement membrane, specifically known as urinary bladder matrix (UBM).	• Management of topical wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4166
<u>Derm-Maxx</u> Freeze-dried decellularized dermal matrix allograft.	• Repair or replacement of damaged or inadequate integumental tissue	Q4238
<u>Derma-Gide</u> Comprised of a porcine derived, porous, purified collagen matrix.	• Management of wounds including, but may not be limited to: ○ Diabetic ulcers ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence)	Q4203

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	
<u>DermaBind CH</u> Dehydrated human ECM chorion derived membrane allograft.	● Wound covering or barrier membrane	Q4288
<u>DermaBind DL</u> Dehydrated human ECM allograft.	● Wound covering or barrier membrane	Q4287
<u>DermaBind FM</u> Dehydrated human placental membrane allograft comprised of an extracellular matrix.	● Wound covering or barrier membrane	Q4313
<u>DermaBind SL</u> Dehydrated human amniotic membrane allograft.	● Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	Q4284
<u>Dermacyte</u> Amniotic membrane allograft.	● Diabetic foot ulcers ● Partial-thickness wounds ● Venous stasis ulcers	Q4248

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
<u>Dermacyte AC Matrix Amniotic Membrane Allograft</u> Human amnion membrane allograft.	Protective barrier or covering	Q4343
<u>DermaMatrix</u> Allograft derived from donated human skin.	Repair, replacement or reinforcement of soft tissue for grafting purposes	Q4100
<u>DermaPure</u> Derived from split-thickness grafts harvested from human cadaver tissue donors.	- Acute and chronic wounds such as: - Diabetic foot ulcers - Venous stasis ulcers - Wounds that are refractory to more conservative care	Q4152
<u>DermaSpan</u> ADM derived from human allograft skin tissue.	- Covering, protection, reinforcement or supplemental support of tendon - Homologous uses of human integument - Repair or replacement of damaged or inadequate integumental tissue	Q4126
<u>Dermavest, Plurivest</u> Amnion/chorion, umbilical cord and placental disk tissue preserved with attachment proteins, growth factors and cytokines.	Skin replacement or supplement for damaged or inadequate integumental tissue such as surgical sites, ulcers or wounds	Q4153
<u>DermMatrix (formerly InteXen) Porcine Dermal Matrix</u> Pyrogen free, porcine dermis.	- Implantation to reinforce soft tissues in gastroenterological, gynecological and urological anatomy - Treatment of hernias where the connective tissue has ruptured	Q4100
<u>Dual Layer Impax Membrane</u> Dehydrated dual layered human amniotic membrane allograft.	Wound covering or barrier membrane	Q4262
<u>DuoAmnion</u> Dehydrated human amniotic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4327
<u>DuraGen</u> Onlay graft comprised of a porous, purified collagen matrix.	Absorbable implant for the repair of dura mater	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>E-Graft</u> Thick layer human amnion rolled membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4318
<u>E-Z Derm</u> Porcine derived xenograft in which the collagen has been chemically cross-linked with aldehyde (a chemical compound).	• Alternative to allografts in the treatment of burn wounds, especially for partial-thickness skin losses • Protection for meshed autografts • Temporary coverage prior to autograft	Q4136
<u>Emerge Matrix</u> Dual layer human amniotic and chorionic membranes.	• Wound covering or barrier membrane, over acute and chronic wounds, including full-thickness ulcers	Q4297
<u>EndoForm Dermal Template</u> ECM derived from ovine forestomach.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
<u>Inverse</u> Dehydrated human amniotic membrane.	Wound covering or barrier membrane, over acute and chronic wounds, including dermal ulcers or defects	Q4258
<u>Epicel</u> Skin cells grown or cultured from a postage stamp sized sample of the individual's own healthy skin.	Replace the epidermis on a severely burned individual	Q4100
<u>Epicord</u> Umbilical cord allograft.	Application over exposed bone, tendon, nerve, muscle, joint capsule, and hardware.	Q4187
<u>Epiefect</u> Human amniotic membrane allograft.	Barrier or cover for acute and chronic wounds	Q4278
<u>Epifix (injectable)</u> Human amniotic membrane allograft.	Protective barrier or covering for acute and chronic wounds	Q4145
<u>Esano A</u> Single-layer, decellularized, dehydrated human amniotic membrane allograft.	Barrier or cover for acute and chronic wounds	Q4272
<u>Esano AAA</u> Tri-layer, decellularized, dehydrated human amniotic membrane allograft.	Barrier or cover for acute and chronic wounds	Q4273
<u>Esano AC</u> Dual-layer, decellularized, dehydrated human amniotic membrane allograft.	Barrier or cover for acute and chronic wounds	Q4274
<u>Esano ACA</u> Tri-layer, decellularized, dehydrated human amniotic membrane allograft.	Barrier or cover for acute and chronic wounds	Q4275
<u>Excellagen</u> Pharmaceutically formulated fibrillar Type I bovine collagen gel.	- Applied immediately following wound debridement - Purported to promote: - Cellular adhesion - Chemotaxis - Migration and proliferation to stimulate granulation tissue formation	Q4149
<u>FloGraft</u> Cryopreserved, injectable, liquid amniotic fluid derived allograft.	Soft tissue repair	Q4100
<u>Floweramnioflo</u>	Replace or supplement damaged or integumental tissue	Q4177

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
Premixed, ambient temperature placental tissue matrix allograft.		
<u>Floweramniopatch</u> Dehydrated amniotic membrane allograft.	• Wound covering	Q4178
<u>Flowerderm</u> Acellular dermal allograft ECM composed of proteoglycans, hyaluronic acid, collagen, fibronectin and elastin.	• Reinforcement of tendons and supplemental support • Wound covering	Q4179
<u>Fluid Flow, Fluid GF</u> Human amniotic flowable allograft.	• Acute and chronic wound therapy • Soft tissue injuries	Q4206
<u>Fortify Flowable</u> Extracellular matrix (ECM) derived from porcine small intestinal submucosa.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A4100, Q4100
<u>Fortiva Porcine Dermis</u> Noncross-linked porcine dermis, designed to act as a scaffold that allows for neovascularization and	• Soft tissue repair procedures such as hernia repair	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
reincorporation with the individual's own tissue.		
<u>GalaFLEX, GalaFLEX 3D and GalaFLEX 3DR</u> Bioresorbable surgical scaffold made of monofilament fibers of the biopolymer, poly-4-hydroxybutarate (P4HB).	- Reinforcing scaffold in soft tissue repair procedures such as: - General soft tissue reconstruction - Plastic and reconstructive surgery	A4100, Q4100
<u>GammaGraft</u> Irradiated human skin allograft acquired from cadaveric donors.	- Temporary graft for treating: - Burns - Chronic wounds - Full-thickness wounds - Partial-thickness wounds	Q4111
<u>Genesis Amniotic Membrane</u> Dehydrated, collagenous human tissue allograft.	- Acute and chronic wound therapy - Soft tissue injuries	Q4198
<u>Grafix PLUS</u> Human chorionic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4304
<u>GraftJacket Xpress</u> Injectable allograft treatment that is mixed with sterile saline.	Facilitate the rapid formation of granulation tissue and reduce infection risk	Q4113
<u>Helicoll</u> Helicoll is an ADM derived from bovine Type-1 collagen.	- Full- and partial-thickness wounds - Second-degree burns - Skin donor sites - Skin ulcers - Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears)	Q4164
<u>hMatrix</u> Acellular, dermal scaffold processed from donated human skin.	- Replace damaged or inadequate integumental tissue such as: - Abdominal wall repair - Breast reconstruction - Wound covering	Q4134
<u>Human Health Factor 10 Amniotic Patch (hhf10-p)</u>	Wound covering or barrier membrane	Q4224

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Single-layer amniotic allograft derived from full-term human birth tissue, specifically the immunoprivileged amnion layer.		
<u>Hyalomatrix</u> Bioresorbable, dermal substitute made of HYAFF, a long-acting derivative of hyaluronic acid providing a microenvironment.	• Full-thickness wounds and burns • Provides a wound preparation to support the implantation of autologous skin grafts	Q4117
<u>InnovaBurn, InnovaMatrix XL</u> Decellularized extracellular matrix (ECM) derived from porcine placental tissue.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2022
<u>InnovaMatrix AC</u> Decellularized extracellular matrix (ECM) topical wound covering derived from porcine placental tissue.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers	A2001

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>InnovaMatrix FS</u> Decellularized extracellular matrix (ECM) topical wound covering derived from porcine placental tissue.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears)	A2013

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>InnovaMatrix PD</u> Decellularized extracellular matrix (ECM) derived from porcine placental tissue.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2023
<u>Integra Flowable Wound Matrix</u> Comprised of granulated cross- linked bovine tendon collagen and glycosaminoglycan; hydrated with saline.	• Difficult to access wound sites, as well as tunneled wounds.	Q4114
<u>Integra HuMend ADM</u> Human dermal allograft that has been decellularized while preserving the noncellular natural biologic components and structure of the dermal matrix.	• Reinforcing scaffold in soft tissue repair procedures such as: ○ Abdominal wall reconstruction ○ Breast reconstruction	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	Tendon protection	
<u>Integra Matrix Wound Dressing</u> Biodegradable, porous matrix of cross-linked bovine tendon and glycosaminoglycan.	Scaffold for cellular invasion and capillary growth	Q4108
<u>Interfyl – Flowable, Particulate</u> Decellularized, connective ECM derived from human placental tissue.	Correct defects and fill voids and in soft tissue, providing mechanical and structural support to facilitate the tissue repair process	Q4171
<u>Keramatrix, Kerasorb</u> Absorbable matrix made from a combination of keratin technology that dissolves into wounds.	Full- and partial-thickness wounds with low to high exudate	Q4165
<u>Kerecis Omega3</u> Acellular intact fish skin that contains proteins, lipids (including omega3) and other skin elements and bioactive lipid content.	- Reconstruction of: - Breast - Burns - Chronic wounds - Dura mater - Hernia repair - Oral wounds	Q4158
<u>Kerecis Omega3 MariGen Shield</u> Acellular intact fish skin that contains proteins, lipids (including omega3) and other skin elements and bioactive lipid content.	- Management of wounds including: - Chronic vascular ulcers - Diabetic ulcers - Draining wounds - Partial- and full-thickness wounds - Pressure ulcers - Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) - Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears)	A2019

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Venous ulcers	
<u>Keroxx</u> Flowable matrix made from a combination of keratin technology that dissolves into wounds.	• Chronic wounds such as: ○ Diabetic ulcers ○ Donor sites/grafts ○ Pressure ulcers	Q4202
<u>Lamellas</u> Dehydrated human resorbable allograft derived from placental tissue.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4292
<u>Lamellas XT</u> Dehydrated human resorbable allograft derived from placental tissue.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4291
<u>Leneva</u> Allograft adipose extracellular matrix (ECM).	• Soft tissue reconstruction	Q4100
<u>MatriDerm</u> Acellular dermal substitute composed of bovine collagen and elastin.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	A2027
<u>Matrion</u> Matrix scaffold derived from an intact decellularized placental membrane	• Chronic wounds	Q4201

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
comprising both amniotic and chorionic layers.		
<u>MatriStem MicroMatrix</u> Noncross-linked basement membrane compromised of urinary bladder matrix (UBM) and various collagens.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4118
<u>Matrix HD</u> Acellular human dermis allograft retains the three-dimensional intertwined multidirectional fibers and mechanical properties of the native tissue architecture.	• Protect, reinforce or cover soft tissue and provide a scaffold to support regenerative processes	Q4128
<u>Matrix HD Allograft Dermis</u> Acellular human dermis allograft.	• Wound covering for: ○ Burns ○ Diabetic foot ulcers	Q4345
<u>Mediskin</u> Frozen irradiated porcine xenograft with a dermal and epidermal layer.	• Meshed autograft protection	Q4135

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	• Partial-thickness skin ulcerations and abrasions • Temporary covering for full-thickness skin loss • Toxic epidermal necrolysis (TEN)	
<u>Membrane Graft, Membrane Wrap</u> Human amniotic allograft.	• Management of wounds including, but may not be limited to: ○ Burns ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Ulcers caused by mixed vascular etiologies ○ Venous ulcers	Q4205
<u>Membrane Wrap-Hydro</u> Human amnion membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4290
<u>MemoDerm</u> ADM derived from human allograft skin tissue.	• Repairs (eg, rotator cuff) and wounds (eg, chronic diabetic ulcer)	Q4126
<u>Microlyte Matrix</u> Synthetic absorbent polyvinyl alcohol hydrogel sheet with a polymeric surface coating containing ionic and metallic silver.	• Management of wounds including, but may not be limited to: ○ Diabetic ulcers ○ First and second-degree burns ○ Partial- and full-thickness wounds	A2005

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, lacerations, skin tears) ○ Venous ulcers	
<u>MicroMatrix Flex</u> Porcine derived extracellular matrix known as urinary bladder matrix.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2028
<u>Miro3D</u> Decellularized extracellular matrix (ECM) derived from porcine liver tissue.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers	A2025

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>Miroderm</u> Noncross-linked acellular wound matrix derived from porcine liver and is processed and stored in a phosphate buffered aqueous solution.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds	Q4175

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Undermined wounds ○ Venous ulcers	
<u>MiroTract Wound Matrix</u> Non-crosslinked acellular wound dressing derived from porcine liver tissue, compressed onto the guidewire of the MiroTract delivery system.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2029
<u>Mirrugen Advanced Wound Matrix</u> Biocompatible and resorbable borate glass fibers and particulate.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds	A2002

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>MLG-Complete</u> Full-thickness amnion-chorion derived allograft.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4256

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>MOST</u> Perforated three-layer amnion/chorion/amnion human amniotic membrane allograft.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4328
<u>MyOwn Skin</u> Autologous, homologous human skin product.	• Chronic wounds • Postsurgical wounds	Q4226
<u>Myriad</u> ECM derived from ovine forestomach.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4100
<u>NeoMatriX Wound Matrix</u> Acellular axolotl dermal extracellular matrix.	• Management of wounds including: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds	A2021

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers	
<u>Neopatch, Therion</u> Terminally sterilized, dehydrated human placental membrane tissue comprised of both amnion and chorion.	● External wound covering for dermal ulcerations including: ○ Chronic venous ulcers ○ Diabetic ulcers	Q4176
<u>Neostim DL</u> Double layer dehydrated amniotic membrane allograft.	● Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds	Q4267

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Neostim Membrane</u> Single layer dehydrated amniotic membrane allograft.	○ Venous ulcers ● Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers	Q4266
<u>Neostim TL</u> Triple layer dehydrated amniotic membrane allograft.	● Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears)	Q4265

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Tunneled/undermined wounds ○ Venous ulcers	
<u>Neox 100</u> Cryopreserved human amniotic membrane and umbilical cord. <u>Clarix 100</u> Cryopreserved human amniotic membrane, umbilical cord and additional proteins.	• Surgical wrap or barrier, quick-peel matrix • Wound covering for dermal ulcers and defects, quick-peel matrix	Q4156
<u>Neox Cord 1K</u> Cryopreserved human amniotic membrane and umbilical cord. <u>Neox Cord RT</u> Hydrated human amniotic membrane allograft. <u>Clarix Cord 1K</u> Cryopreserved human amniotic membrane, umbilical cord and additional proteins.	• Surgical cover, wrap or barrier	Q4148
<u>Neox Flo, Clarix Flo</u> Particulate products of the above-mentioned matrices.	• Replace or supplement damaged or inadequate integumental tissue	Q4155
<u>NeuroMend Nerve Wrap</u> Resorbable, semipermeable, type I collagen nerve wrap.	• Peripheral nerve repair	C9361
<u>Novachor</u> Chorion layer of the placental membranes.	• Onlay graft for: ○ Acute and chronic wounds including neuropathic ulcers, pressure ulcers and venous stasis ulcers ○ Burns ○ Postsurgical wounds ○ Posttraumatic wounds	Q4194

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Novafix</u> Dehydrated human amniotic membrane allograft.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4208
<u>Novafix DL</u> Dehydrated human amnion chorion membrane allograft.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers	Q4254

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>NovoGen</u> Absorbable, nonpyrogenic bovine type I collagen and 45S5 bioactive glass.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	Q4100
<u>NuCel</u> Allograft derived from human amnion and amniotic fluid.	● Provides an environment for tissue growth, repair and healing	Q4100
<u>NuDyn, SurFactor</u> Acellular, flowable human amniotic membrane allograft.	● Acute and chronic wounds ● Burns ● Soft tissue injuries	Q4233

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>NuDYN DL, NuDYN DL MESH</u> Human amnion/chorion membrane allografts.	• Surgical wounds • Barrier or cover for acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	Q4285
<u>NuDYN SL, NuDYN SLW</u> Human amnion membrane allografts.	• Barrier or cover for acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers	Q4286

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>NuShield</u> Allograft derived from amniotic and chorionic membranes.	● Assist in healing of soft tissue injuries ● Barrier protection of dura, nerves and tendons ● Burns ● Wound covering	Q4160
<u>Oasis Burn Matrix</u> Naturally derived, ECM created from the submucosal layer of porcine small intestine.	● Acellular scaffold that accommodates remodeling of host tissue	Q4103
<u>ologen Collagen Matrix</u> Biodegradable porcine-derived collagen matrix.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Oral wounds/sores ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Trauma wounds (eg, second-degree burns) ○ Venous ulcers	
<u>Omeza Collagen Matrix</u> Hydrolyzed fish collagen infused with cod liver oil.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2014
<u>Orion</u> Dual layer, dehydrated human amniotic membrane allograft.	• Barrier or cover for acute and chronic wounds	Q4276
<u>OrthoFlo</u> Allograft derived from amniotic fluid.	• For use in joints to: ○ Modulate inflammation ○ Protect and cushion ○ Provide lubrication for enhanced mobility	Q4100
<u>OviTex</u> Bio scaffold composed of ovine (sheep) derived ECM and polyglycolic acid (PGA).	• Reinforce and/or repair soft tissue where weakness exists	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	Repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material	
<u>PalinGen or PalinGen Xplus (PalinGen Membrane; PalinGen Hydromembrane; PalinGen XPlus Membrane and PalinGen XPlus Hydromembrane)</u> Human amniotic tissue allograft comprised of amnion and amniotic fluid.	- Aid in healing and repair of wounds - Wound covering and support for native tissue	Q4173
<u>PalinGen or ProMatrX (ProMatrX, PalinGen Flow and PalinGen SportFlow)</u> Human liquid allograft comprised of amnion and amniotic fluid.	Aid in healing and repair of chronic wounds	Q4174
<u>PelloGraft</u> Dual layer human amniotic/chorion membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4320
<u>Permacol</u> A porcine dermal collagen implant.	- Patch to reinforce soft tissue where weakness occurs - Surgical repair of damaged or ruptured soft tissue	C9364
<u>PermeaDerm B</u> Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.	- Partial-thickness burns - Skin donor sites	A2016
<u>PermeaDerm C</u> Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.	- Management of wounds including, but may not be limited to: - Chronic vascular ulcers - Diabetic ulcers - Draining wounds - Partial-thickness wounds - Pressure ulcers	A2018

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	
<u>PermeaDerm Glove</u> Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.	• Debrided partial-thickness hand burns	A2017
<u>Phoenix Wound Matrix</u> Bioabsorbable, conformable, non-woven, fibrous, three-dimensional matrix. Composed of poly(lactide-co-caprolactone) and polyglycolic acid.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds	A2015

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Venous ulcers	
<u>PolyCyte</u> Minimally manipulated human tissue allograft derived from the Wharton's jelly of the umbilical cord.	● Replace or supplement damaged or inadequate tissue	Q4241
<u>PRECLUDE Vessel Guard</u> Three-layer construction with two outer layers consisting of a tight expanded polytetrafluoroethylene (ePTFE) microstructure.	● Cover for vessels following anterior vertebral surgery, providing a plane of dissection	Q4100
<u>PriMatrix</u> ADM derived from fetal bovine skin.	● Scaffold capable of being integrated, remodeled and eventually replaced by functional host tissue	Q4110
<u>Procenta</u> Acellular, sterile human placental derived allograft.	● Protective barrier, covering or to retain fluid for acute and chronic wounds	Q4310
<u>ProgenaMatrix</u> Human keratin matrix derived from human hair.	● Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ First and second-degree burns ○ Partial- and full-thickness wounds ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, lacerations, skin tears) ○ Venous ulcers	Q4222
<u>ProLayer</u> Human acellular dermal matrix.	● Reinforcement of soft tissue including: ○ Breast reconstruction	Q4100
<u>Promogran Matrix</u>	● Bind and protect the functionality of growth factors, such as platelet-derived growth	Q4100

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
Freeze-dried composite prepared from bone collagen and oxidized regenerated cellulose.	factors (PDGF) in hostile proteolytic environments	
<u>PuraPly, PuraPly AM, PuraPly XT</u> Purified Type 1 native collagen matrix creates a durable biocompatible scaffold.	- Barrier against a wide array of microorganisms - Inhibit formation of biofilm on the wound surface	Q4195, Q4196, Q4197
<u>Puros Dermis</u> A natural biological matrix.	- Periodontal/peri-implant soft tissue management - Soft tissue enhancement	Q4100
<u>Rebound Matrix</u> Dehydrated human allograft derived from placental tissue.	Wound covering or barrier membrane, over acute and chronic wounds, including full-thickness ulcers and other skin defects	Q4296
<u>Reeva FT</u> Dehydrated human amniotic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4314
<u>RegeneLink Amniotic Membrane Allograft</u> Full thickness human amniotic/chorion membrane allograft.	Wound covering or barrier membrane	Q4315
<u>REGUaRD</u> Hydrated acellular human dermal allograft matrix.	- Burns - Chronic, nonhealing wounds	Q4255
<u>Relese</u> Dehydrated human amniotic membrane obtained from donated placental tissue.	Acute and chronic wounds including dermal ulcers and other defects	Q4257
<u>RenoGraft</u> Triple layer human amniotic/chorion membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4321
<u>Repliform</u> Acellular human dermis.	Pelvic floor repair	Q4100
<u>Repriza</u> Pre hydrated, ready to use, ADM prepared from human skin allograft.	- Reconstructive surgery wherever an ADM may be used including, but may not be limited to: - Abdominal wall reconstruction - Augmentation of soft tissue irregularities - Breast reconstruction	Q4143

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Resolve Matrix</u> Non-crosslinked acellular wound dressing derived from porcine peritoneum membrane.	• Management of topical wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2024
<u>Restorigin</u> Amnion umbilical cord tissue.	• Burns • Chronic, nonhealing wounds	Q4191, Q4192
<u>Restrata</u> Resorbable nanofiber wound matrix.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers	A2007, A2026

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	
<u>Revita</u> Dehydrated, sterile human amniotic membrane and chorionic membrane.	● Acute and chronic wounds, including defects and dermal ulcers ● Wound covering or barrier membrane	Q4180
<u>Revitalon</u> Composed of native human amnion and chorion in addition to collagen and growth factors.	● Damaged membranes ● Dressing for burns ● Full-thickness wounds	Q4157
<u>RevoShield + Amniotic Barrier</u> Dual layer amniotic membrane.	● Wound covering or barrier membrane, over acute and chronic wounds	Q4289
<u>RX Flow, RX Membrane</u> Placental connective tissue matrix.	● Surgical use to supplement or replace damaged or inadequate connective tissue	Q4100
<u>SanoGraft</u> Dehydrated single layer human amniotic membrane allograft.	● Wound covering or barrier membrane, over acute and chronic wounds	Q4319
<u>Sanopellis</u> Human amniotic membrane allograft.	● Protective barrier or covering for acute and chronic wounds including partial and full thickness wounds	Q4308
<u>Signature APatch</u> Amniotic membrane allograft.	● Repair of acute and chronic wounds including, but may not be limited to: ○ Burns ○ Diabetic foot ulcers ○ Pressure ulcers ○ Surgical wounds ○ Venous leg ulcers	Q4260

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	Wounds with exposed bone, muscle and/or tendon	
<u>SimpliDerm</u> Human acellular dermal matrix.	- Replacement of damaged or inadequate integumental tissue - Soft tissue defects	Q4100
<u>SimpliGraft</u> Single layer human amnion membrane allograft.	Barrier and protective coverage from the surrounding environment	Q4340
<u>SimpliMax</u> Dual layer human amnion membrane allograft.	Barrier and protective coverage from the surrounding environment	Q4341
<u>Singlay</u> Perforated single layer human amniotic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4329
<u>SkinTE</u> Autologous, homologous, full –thickness skin product composed of viable skin cells and an organized extracellular matrix.	- Burns - Chronic wounds - Homologous uses of human integument	Q4200
<u>StrataGraft</u> Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat.	Adults with thermal burns containing intact dermal elements (eg, deep partial-thickness burns)	Q4100
<u>Strattice Reconstructive Tissue Matrix</u> Derived from porcine dermis, which undergoes nondamaging processing that removes cells and reduces the key component in the xenogeneic rejection response.	- Surgical repair of damaged or ruptured soft tissue - Surgically implanted patch to reinforce where weakness exists	Q4130
<u>Stravix, StravixPL</u> Cryopreserved human placental tissue composed of umbilical amnion and Wharton's jelly.	Wrap to aid in surgical procedures and wound repair	Q4133
<u>Supra SDRM</u> Biodegradable matrix wound dressing fabricated from a tri-polymer of polylactide, trimethylene carbonate, ε-caprolactone and polyvinyl alcohol.	- Acute and chronic wounds such as: - Burns - Chronic vascular ulcers - Diabetic ulcers	A2011

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	
<u>Suprathel</u> Bioresorbable dermal covering, composed entirely of synthetic materials, including a tripolymer of polylactide, s-caprolactone and trimethylene carbonate.	• Dermal wounds such as: ○ Abrasions ○ Burns ○ Split-thickness skin graft donor sites	A2012
<u>SureDerm</u> Human acellular dermal matrix.	• Burns • Periodontal soft tissue management • Skin ulcers	Q4220
<u>SurgiCORD</u> Umbilical tissue membrane allograft.	• Management of wounds including, but may not be limited to: ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pressure injuries ○ Venous stasis ulcers	Q4218
<u>Surgigraft</u> Human amnion-only regenerative extracellular tissue matrix.	• Management of wounds including, but may not be limited to: ○ Adhesion barrier ○ Burn wounds ○ Diabetic ulcers ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pre- and post-surgical wounds ○ Pressure injuries ○ Scar tissue	Q4183

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
	○ Venous stasis ulcers	
<u>SurgiGRAFT-DUAL</u> Minimally processed bilayer allograft.	• Management of wounds including, but may not be limited to: ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pressure injuries	Q4219
<u>SurgiMend Collagen Matrix</u> Acellular tissue matrix of either fetal or neonatal bovine origin.	• Breast reconstruction • Reinforcement for weak or damaged soft tissues	C9358, C9360
<u>SurGraft</u> Dehydrated amniotic membrane sheet.	• Management of wounds including, but may not be limited to: ○ Burns ○ Diabetic ulcers ○ Full- and partial-thickness wounds ○ Pressure wounds ○ Surgical wounds ○ Venous ulcers	Q4209
<u>SurGraft FT</u> Full-thickness amnion/chorion tissue allograft.	• Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears)	Q4268

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Tunneled/undermined wounds ○ Venous ulcers	
<u>SurGraft TL</u> Triple layer amniotic tissue allograft.	● Repair of acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Venous ulcers	Q4263
<u>SurGraft XT</u> Dual layer amniotic tissue allograft.	● Acute and chronic wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers	Q4269

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
	○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers	
<u>Symphony</u> Extracellular matrix (ECM) derived from ovine forestomach tissue.	• Management of wounds including, but may not be limited to: ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers	A2009
<u>TAG</u> Triple layer amniotic allograft derived from placental tissue.	• Wound covering or barrier membrane, over acute and chronic wounds	Q4261

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
<u>Talymed</u> Advanced matrix composed of shortened fibers isolated from microalgae.	• Management of wounds including, but may not be limited to: ○ Abrasions ○ Chronic vascular ulcers ○ Dehisced surgical wounds ○ Diabetic ulcers ○ Donor sites/grafts ○ Full- and partial-thickness wounds ○ Lacerations ○ Post-laser surgery and other bleeding surface wounds ○ Post-Mohs surgery ○ Pressure wounds ○ Second-degree burns ○ Surgical wounds ○ Traumatic wounds healing by secondary intention ○ Ulcers caused by mixed vascular etiologies ○ Venous ulcers	Q4127
<u>TenSIX Acellular Dermal Matrix</u> Acellular matrix with natural histomorphology preserved.	• Tendon and wound coverage	Q4146
<u>TheraGenesis</u>	• Management of wounds including, but may not be limited to:	A2008

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Bilayered wound matrix comprised of a porcine tendon-derived atelocollagen layer and a silicone film layer.	○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers	
<u>Theramend</u> Patch product from human amnion membrane allograft that can be meshed or fenestrated.	● Covering or barrier for acute or chronic wounds	Q4342
<u>TheraSkin</u> Biologically active cryopreserved human skin allograft with both epidermis and dermis layers; the cellular and extracellular composition provides a supply of collagen, cytokines and growth factors.	● Management of wounds including, but may not be limited to: ○ Dehisced surgical wounds ○ Diabetic foot ulcers ○ Necrotizing fasciitis ○ Pressure ulcers ○ Radiation burns ○ Venous leg ulcers ● Repair of skin over any wound including those with exposed bone, capsule, muscle or tendon	Q4121
<u>TissueMend</u> Remodeled collagen matrix created from bovine skin.	● Reinforcement of soft tissue that is repaired using sutures or anchors during tendon repair surgery	Q4100
<u>TOTAL</u>	● Wound covering or barrier membrane, over acute and chronic wounds	Q4330

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Perforated human amniotic/chorion membrane allograft.		
<u>TranZgraft (InteguPly)</u> ADM derived from human allograft skin tissue.	• Replace or supplement damaged or inadequate integumental tissue for acute and chronic wounds including, but may not be limited to: ○ Diabetic foot ulcers ○ Pressure ulcers ○ Venous leg ulcers	Q4126
<u>Tri-Membrane Wrap</u> Human amnion membrane allograft.	• Protective barrier or covering for acute and chronic wounds	Q4344
<u>Truskin</u> Split-thickness, cryopreserved skin allograft extracellular matrix with growth factors and endogenous living skin cells.	• Repair of acute and chronic wounds including, but may not be limited to: ○ Diabetic foot ulcers ○ Pressure ulcers ○ Surgical wounds ○ Venous leg ulcers ○ Wounds with exposed bone and tendon	Q4167
<u>Vendaje</u> Dehydrated human amniotic membrane composed of the amnion layer.	• Support and serve as a barrier for integumental tissue	Q4252
<u>Vendaje AC</u> Decellularized amniotic and chorionic allograft derived from placental tissue.	• Protective covering for soft tissue wounds	Q4279
<u>Veritas Collagen Matrix</u> Acellular tissue matrix derived from bovine pericardium.	• Hernia repair • Pelvic floor procedures • Plastic and reconstructive procedures	C9354
<u>Via Matrix</u> Full-thickness amnion and chorion allograft.	• Protective barrier or covering for acute and chronic wounds or burns	Q4309
<u>Viaflow, Viaflow C</u> Flowable placental tissue matrices.	• Breast reconstruction • Tissue voids and defects	Q4100
<u>VIM</u> Allograft sheet of human amnion.	• Barrier for the following types of surgeries: ○ Ophthalmic ○ Orthopedic • Wound covering	Q4251

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/CPT® Code(s)
<u>VitoGraft</u> Dual layer human amniotic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4317
<u>WoundPlus</u> Dehydrated human amniotic membrane allograft.	Wound covering or barrier membrane, over acute and chronic wounds	Q4326
<u>Xcell Amnio Matrix</u> Lyophilized amniotic membrane allograft.	- Acute and chronic wounds including, but may not be limited to: - Chronic vascular ulcers - Diabetic ulcers - Partial- and full-thickness wounds - Pressure ulcers - Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) - Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) - Tunneled/undermined wounds - Venous ulcers	Q4280
<u>XCellerate</u> Lyophilized human amniotic membrane allograft.	- Burns - Chronic, nonhealing wounds	Q4234
<u>XCM Biologic Tissue Matrix</u> Noncross-linked 3-D matrix derived from porcine dermis.	- Reinforcement and repair of soft tissue where weakness exists, including plastic and reconstructive surgical applications - Reinforcement of soft tissues which are repaired by suture or suture anchors	Q4142
<u>Xelma</u> ECM protein	Hard to heal wounds such as venous leg ulcers	Q4100
<u>XWrap</u>	Soft tissue defects and wounds	Q4204

Skin / Tissue Substitute	Purported Indications	Associated HCPCS/ CPT® Code(s)
Resorbable, chorion-free, human amnion allograft.		
Zenapro Combination of ultra-lightweight polypropylene and small intestinal submucosa (SIS).	Repair of a body wall defect or hernia requiring the addition of a reinforcing or bridging material	Q4100
Zenith Amniotic Membrane Dehydrated amniotic membrane allograft.	- Acute and chronic wound therapy - Application in difficult to access wound sites, deep dermal wounds and irregularly shaped wounds	Q4253

Humana members may **NOT** be eligible under the Plan for any other skin or tissue substitutes not addressed in the [Coverage Determination](#) section. These are considered experimental/investigational as they are not identified as widely used and generally accepted for the proposed uses as reported in nationally recognized peer-reviewed medical literature published in the English language.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	
CPT® Category III Code(s)	Description	
HCPCS Code(s)	Description	
A2001	InnovaMatrix AC, per sq cm	
A2002	Mirragen Advanced Wound Matrix, per sq cm	
A2005	Microlyte Matrix, per sq cm	
A2007	Restrata, per sq cm	
A2008	TheraGenesis, per sq cm	
A2009	Symphony, per sq cm	
A2010	Apis, per sq cm	

A2011	Supra sdrm, per square centimeter	
A2012	Suprathel, per square centimeter	
A2013	Innovamatrix fs, per square centimeter	
A2014	Omeza collagen matrix, per 100 mg	
A2015	Phoenix wound matrix, per square centimeter	
A2016	Permeaderm b, per square centimeter	
A2017	Permeaderm glove, each	
A2018	Permeaderm c, per square centimeter	
A2019	Kerecis omega3 marigen shield, per square centimeter	
A2020	Ac5 advanced wound system (ac5)	
A2021	Neomatrix, per square centimeter	
A2022	Innovaburn or innovamatrix xl, per square centimeter	
A2023	Innovamatrix pd, 1 mg	
A2024	Resolve matrix, per square centimeter	
A2025	Miro3d, per cubic centimeter	
A2026	Restrata minimatrix, 5 mg	
A2027	Matriderm, per square centimeter	
A2028	Micromatrix flex, per mg	
A2029	Mirotract wound matrix sheet, per cubic centimeter	
A4100	Skin substitute, fda cleared as a device, not otherwise specified	
C1832	Autograft suspension, including cell processing and application, and all system components	
C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm	
C9358	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	
C9360	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	
C9361	Collagen matrix nerve wrap (NeuroMend Collagen Nerve Wrap), per 0.5 cm length	
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm	
C9364	Porcine implant, Permacol, per sq cm	
Q4100	Skin substitute, not otherwise specified	
Q4101	Apligraf, per sq cm	
Q4102	Oasis wound matrix, per sq cm	
Q4103	Oasis burn matrix, per sq cm	
Q4104	Integra bilayer matrix wound dressing (BMWD), per sq cm	
Q4105	Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix, per sq cm	
Q4106	Dermagraft, per sq cm	
Q4107	GRAFTJACKET, per sq cm	
Q4108	Integra matrix, per sq cm	
Q4110	PriMatrix, per sq cm	

Q4111	GammaGraft, per sq cm	
Q4112	Cymetra, injectable, 1 cc	
Q4113	GRAFTJACKET XPRESS, injectable, 1 cc	
Q4114	Integra flowable wound matrix, injectable, 1 cc	
Q4115	AlloSkin, per sq cm	
Q4116	AlloDerm, per sq cm	
Q4117	HYALOMATRIX, per sq cm	
Q4118	MatriStem micromatrix, 1 mg	
Q4121	TheraSkin, per sq cm	
Q4122	DermACELL, DermACELL AWM or DermACELL AWM Porous, per sq cm	
Q4123	AlloSkin RT, per sq cm	
Q4124	OASIS ultra tri-layer wound matrix, per sq cm	
Q4125	ArthroFlex, per sq cm	
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm	
Q4127	Talymed, per sq cm	
Q4128	FlexHD, AllopatchHD, or Matrix HD, per sq cm	
Q4130	Strattice TM, per sq cm	
Q4132	Grafix Core and GrafixPL Core, per sq cm	
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm	
Q4134	HMatrix, per sq cm	
Q4135	Mediskin, per sq cm	
Q4136	E-Z Derm, per sq cm	
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm	
Q4138	BioDFence DryFlex, per sq cm	
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc	
Q4140	BioDFence, per sq cm	
Q4141	AlloSkin AC, per sq cm	
Q4142	XCM biologic tissue matrix, per sq cm	
Q4143	Repriza, per sq cm	
Q4145	EpiFix, injectable, 1 mg	
Q4146	Tensix, per sq cm	
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm	
Q4149	Excellagen, 0.1 cc	
Q4150	AlloWrap DS or dry, per sq cm	
Q4151	AmnioBand or Guardian, per sq cm	
Q4152	DermaPure, per sq cm	
Q4153	Dermavest and Plurivest, per sq cm	
Q4154	Biovance, per sq cm	
Q4155	Neox Flo or Clarix Flo 1 mg	
Q4156	Neox 100 or Clarix 100, per sq cm	

Q4157	Revitalon, per sq cm	
Q4158	Kerecis Omega3, per sq cm	
Q4159	Affinity, per sq cm	
Q4160	Nushield, per sq cm	
Q4161	bio-ConneKt wound matrix, per sq cm	
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc	
Q4163	WoundEx, BioSkin, per sq cm	
Q4164	Helicoll, per sq cm	
Q4165	Keramatrix or Kerasorb, per sq cm	
Q4166	Cytal, per sq cm	
Q4167	Truskin, per sq cm	
Q4168	AmnioBand, 1 mg	
Q4169	Artacent wound, per sq cm	
Q4170	Cygnus, per sq cm	
Q4171	Interfyl, 1 mg	
Q4173	PalinGen or PalinGen XPlus, per sq cm	
Q4174	PalinGen or ProMatrX, 0.36 mg per 0.25 cc	
Q4175	Miroderm, per sq cm	
Q4176	Neopatch or therion, per square centimeter	
Q4177	FlowerAmnioFlo, 0.1 cc	
Q4178	FlowerAmnioPatch, per sq cm	
Q4179	FlowerDerm, per sq cm	
Q4180	Revita, per sq cm	
Q4181	Amnio Wound, per sq cm	
Q4182	Transcyte, per sq cm	
Q4183	Surgigraft, per sq cm	
Q4184	Cellesta or Cellesta Duo, per sq cm	
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5 cc	
Q4186	Epifix, per sq cm	
Q4187	Epicord, per sq cm	
Q4188	AmnioArmor, per sq cm	
Q4189	Artacent AC, 1 mg	
Q4190	Artacent AC, per sq cm	
Q4191	Restorigin, per sq cm	
Q4192	Restorigin, 1 cc	
Q4193	Coll-e-Derm, per sq cm	
Q4194	Novachor, per sq cm	
Q4195	PuraPly, per sq cm	
Q4196	PuraPly AM, per sq cm	
Q4197	PuraPly XT, per sq cm	
Q4198	Genesis Amniotic Membrane, per sq cm	
Q4199	Cygnus matrix, per sq cm	
Q4200	SkinTE, per sq cm	

Q4201	Matrion, per sq cm	
Q4202	Keroxx (2.5 g/cc), 1 cc	
Q4203	Derma-Gide, per sq cm	
Q4204	XWRAP, per sq cm	
Q4205	Membrane Graft or Membrane Wrap, per sq cm	
Q4206	Fluid Flow or Fluid GF, 1 cc	
Q4208	Novafix, per sq cm	
Q4209	SurGraft, per sq cm	
Q4211	Amnion Bio or AxoBioMembrane, per sq cm	
Q4212	AlloGen, per cc	
Q4213	Ascent, 0.5 mg	
Q4214	Cellesta Cord, per sq cm	
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg	
Q4216	Artacent Cord, per sq cm	
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm	
Q4218	SurgiCORD, per sq cm	
Q4219	SurgiGRAFT-DUAL, per sq cm	
Q4220	BellaCell HD or Surederm, per sq cm	
Q4221	Amnio Wrap2, per sq cm	
Q4222	ProgenaMatrix, per sq cm	
Q4224	Human health factor 10 amniotic patch (hhf10-p), per square centimeter	
Q4225	Amniobind, per square centimeter	
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm	
Q4227	AmnioCore™, per sq cm	
Q4229	Cogenex Amniotic Membrane, per sq cm	
Q4230	Cogenex Flowable Amnion, per 0.5 cc	
Q4231	Corplex P, per cc	
Q4232	Corplex, per sq cm	
Q4233	SurFactor or NuDyn, per 0.5 cc	
Q4234	XCellerate, per sq cm	
Q4235	AMNIOREPAIR or AltiPly, per sq cm	
Q4236	Carepatch, per square centimeter	
Q4237	Cryo-Cord, per sq cm	
Q4238	Derm-Maxx, per sq cm	
Q4239	Amnio-Maxx or Amnio-Maxx Lite, per sq cm	
Q4240	CoreCyte, for topical use only, per 0.5 cc	
Q4241	PolyCyte, for topical use only, per 0.5 cc	
Q4242	AmnioCyte Plus, per 0.5 cc	
Q4245	AmnioText, per cc	
Q4246	CoreText or ProText, per cc	

Q4247	Amniotext patch, per sq cm	
Q4248	Dermacyte Amniotic Membrane Allograft, per sq cm	
Q4249	AMNIPLY, for topical use only, per sq cm	
Q4250	AmnioAmp-MP, per sq cm	
Q4251	Vim, per sq cm	
Q4252	Vendaje, per sq cm	
Q4253	Zenith Amniotic Membrane, per sq cm	
Q4254	Novafix DL, per sq cm	
Q4255	REGUaRD, for topical use only, per sq cm	
Q4256	Mlg-complete, per square centimeter	
Q4257	Relese, per square centimeter	
Q4258	Enverse, per square centimeter	
Q4259	Celera dual layer or celera dual membrane, per square centimeter	
Q4260	Signature apatch, per square centimeter	
Q4261	Tag, per square centimeter	
Q4262	Dual layer impax membrane, per square centimeter	
Q4263	Surgraft tl, per square centimeter	
Q4264	Cocoon membrane, per square centimeter	
Q4265	Neostim tl, per square centimeter	
Q4266	Neostim membrane, per square centimeter	
Q4267	Neostim dl, per square centimeter	
Q4268	Surgraft ft, per square centimeter	
Q4269	Surgraft xt, per square centimeter	
Q4270	Complete sl, per square centimeter	
Q4271	Complete ft, per square centimeter	
Q4272	Esano a, per square centimeter	
Q4273	Esano aaa, per square centimeter	
Q4274	Esano ac, per square centimeter	
Q4275	Esano aca, per square centimeter	
Q4276	Orion, per square centimeter	
Q4277	Woundplus membrane or e-graft, per square centimeter	
Q4278	Epieffect, per square centimeter	
Q4279	Vendaje ac, per square centimeter	
Q4280	Xcell amnio matrix, per square centimeter	
Q4281	Barrera sl or barrera dl, per square centimeter	
Q4282	Cygnus dual, per square centimeter	
Q4283	Biovance tri-layer or biovance 3l, per square centimeter	
Q4284	Dermabind sl, per square centimeter	
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter	
Q4286	Nudyn sl or nudyn slw, per square centimeter	
Q4287	Dermabind dl, per square centimeter	
Q4288	Dermabind ch, per square centimeter	

Q4289	Revoshield + amniotic barrier, per square centimeter	
Q4290	Membrane wrap-hydro, per square centimeter	
Q4291	Lamellas xt, per square centimeter	
Q4292	Lamellas, per square centimeter	
Q4293	Acesso dl, per square centimeter	
Q4294	Amnio quad-core, per square centimeter	
Q4295	Amnio tri-core amniotic, per square centimeter	
Q4296	Rebound matrix, per square centimeter	
Q4297	Emerge matrix, per square centimeter	
Q4298	Amniocore pro, per square centimeter	
Q4299	Amnicore pro+, per square centimeter	
Q4300	Acesso tl, per square centimeter	
Q4301	Activate matrix, per square centimeter	
Q4302	Complete aca, per square centimeter	
Q4303	Complete aa, per square centimeter	
Q4304	Grafix plus, per square centimeter	
Q4305	American amnion ac tri-layer, per square centimeter	
Q4306	American amnion ac, per square centimeter	
Q4307	American amnion, per square centimeter	
Q4308	Sanopellis, per square centimeter	
Q4309	Via matrix, per square centimeter	
Q4310	Procenta, per 100 mg	
Q4311	Acesso, per square centimeter	
Q4312	Acesso ac, per square centimeter	
Q4313	Dermabind fm, per square centimeter	
Q4314	Reeva ft, per square centimeter	
Q4315	Regenelink amniotic membrane allograft, per square centimeter	
Q4316	Amchoplast, per square centimeter	
Q4317	Vitograft, per square centimeter	
Q4318	E-graft, per square centimeter	
Q4319	Sanograft, per square centimeter	
Q4320	Pellograft, per square centimeter	
Q4321	Renograft, per square centimeter	
Q4322	Caregraft, per square centimeter	
Q4323	Alloply, per square centimeter	
Q4324	Amniotx, per square centimeter	
Q4325	Acapatch, per square centimeter	
Q4326	Woundplus, per square centimeter	
Q4327	Duoamnion, per square centimeter	
Q4328	Most, per square centimeter	
Q4329	Singlay, per square centimeter	
Q4330	Total, per square centimeter	
Q4331	Axolotl graft, per square centimeter	

Q4332	Axolotl dualgraft, per square centimeter	
Q4333	Ardeograft, per square centimeter	
Q4334	Amnioplast 1, per square centimeter	
Q4335	Amnioplast 2, per square centimeter	
Q4336	Artacent c, per square centimeter	
Q4337	Artacent trident, per square centimeter	
Q4338	Artacent velos, per square centimeter	
Q4339	Artacent vericlen, per square centimeter	
Q4340	Simpligraft, per square centimeter	
Q4341	Simplimax, per square centimeter	
Q4342	Theramend, per square centimeter	
Q4343	Dermacyte ac matrix amniotic membrane allograft, per square centimeter	
Q4344	Tri-membrane wrap, per square centimeter	
Q4345	Matrix hd allograft dermis, per square centimeter	

References

1. Agency for Healthcare Research and Quality (AHRQ). Technical Brief. Skin substitutes for treating chronic wounds. <https://ahrq.gov>. Published February 2, 2020.
2. ECRI Institute. Clinical Evidence Assessment. Affinity amniotic allograft (Organogenesis, Inc.) for treating diabetic foot ulcers. <https://ecri.org>. Published September 15, 2015. Updated June 20, 2024.
3. ECRI Institute. Clinical Evidence Assessment. AlloDerm regenerative tissue matrix (AbbVie, Inc.) for reconstructing breast tissue. <https://ecri.org>. Published December 18, 2018. Updated November 30, 2023.
4. ECRI Institute. Clinical Evidence Assessment. Amnioband allograft placental matrix (MTF Biologics) for treating chronic wounds. <https://ecri.org>. Published June 20, 2016. Updated September 23, 2020.
5. ECRI Institute. Clinical Evidence Assessment. Apligraf (Organogenesis, Inc.) for treating venous leg ulcers. <https://ecri.org>. Published December 2, 2022. Updated April 11, 2023.
6. ECRI Institute. Clinical Evidence Assessment. Arthroflex acellular dermal matrix (LifeNet Health and Arthrex, Inc.) for repairing large to massive rotator cuff tears. <https://ecri.org>. Published October 23, 2017. Updated June 16, 2022.
7. ECRI Institute. Clinical Evidence Assessment. AxoGuard nerve protector (AxoGen, Inc.) for treating peripheral nerve injuries. <https://ecri.org>. Published August 9, 2023.
8. ECRI Institute. Clinical Evidence Assessment. Biodesign sinonasal repair graft (Cook Medical, Inc.) for repairing sinus and nasal cavity defects. <https://ecri.org>. Published December 9, 2021.

9. ECRI Institute. Clinical Evidence Assessment. Biovance amniotic membrane allograft (Celularity, Inc.) for treating chronic wounds. <https://ecri.org>. Published January 3, 2017. Updated July 24, 2020.
10. ECRI Institute. Clinical Evidence Assessment. Cortiva and Cortiva 1 mm allograft dermis (RTI Surgical, Inc.) for breast reconstruction. <https://ecri.org>. Published November 13, 2018. Updated November 30, 2020.
11. ECRI Institute. Clinical Evidence Assessment. Cygnus amniotic allografts (Vivex Medical, Inc.) for treating chronic wounds. <https://ecri.org>. Published April 29, 2022.
12. ECRI Institute. Clinical Evidence Assessment. Dermacell advanced decellularized dermis (LifeNet Health Bio-Implants Division) for breast reconstruction. <https://ecri.org>. Published August 15, 2016. Updated December 2, 2020.
13. ECRI Institute. Clinical Evidence Assessment. Dermacell AWM (LifeNet Health Bio-Implants Division) for chronic wounds. <https://ecri.org>. Published March 8, 2018. Updated December 18, 2020.
14. ECRI Institute. Clinical Evidence Assessment. DermaPure decellularized dermal allograft (ARMS Medical) for treating acute or chronic wounds. <https://ecri.org>. Published November 6, 2024.
15. ECRI Institute. Clinical Evidence Assessment. FlexHD pliable acellular hydrated dermis (Musculoskeletal Transplant Foundation) for breast reconstruction. <https://ecri.org>. Published October 30, 2015. Updated November 8, 2023.
16. ECRI Institute. Clinical Evidence Assessment. Fortify Flowable extracellular matrix (Sanara Medtech, Inc.) for treating wounds. <https://ecri.org>. Published October 3, 2022.
17. ECRI Institute. Clinical Evidence Assessment. GalaFlex surgical scaffold (Galatea Surgical, Inc.) for soft-tissue reinforcement in breast reconstruction surgery. <https://ecri.org>. Published October 7, 2022.
18. ECRI Institute. Clinical Evidence Assessment. Gentrix surgical matrix (ACell, Inc.) for hiatal hernia repair. <https://ecri.org>. Published July 22, 2020.
19. ECRI Institute. Clinical Evidence Assessment. Grafix cellular repair matrix (Osiris Therapeutics, Inc.) for treating chronic wounds. <https://ecri.org>. Published November 9, 2012. Updated July 14, 2021.
20. ECRI Institute. Clinical Evidence Assessment. Hyalomatrix tissue reconstruction matrix (Anika Therapeutics, Inc.) for treating chronic wounds. <https://ecri.org>. Published June 7, 2018. Updated April 13, 2021.
21. ECRI Institute. Clinical Evidence Assessment. Integra bilayer matrix (Integra LifeSciences Corp.) for treating diabetic foot ulcers. <https://ecri.org>. Published April 8, 2021.
22. ECRI Institute. Clinical Evidence Assessment. Leneva allograft adipose matrix (MTF Biologics) for treating wounds. <https://ecri.org>. Published October 3, 2022.

23. ECRI Institute. Clinical Evidence Assessment. Matriderm acellular dermal matrix (MedSkin Solutions) for treating burns. <https://ecri.org>. Published April 19, 2023.
24. ECRI Institute. Clinical Evidence Assessment. Matriderm (MedSkin Solutions) for managing wounds following otorhinolaryngology surgery. <https://ecri.org>. Published April 11, 2022.
25. ECRI Institute. Clinical Evidence Assessment. Mirragen advanced wound matrix (ETS Wound Care LLC) for treating diabetic foot ulcers. <https://ecri.org>. Published October 4, 2023.
26. ECRI Institute. Clinical Evidence Assessment. Myriad soft-tissue matrix (Aroa Biosurgery Ltd.) for treating chronic wounds. <https://ecri.org>. Published September 21, 2020.
27. ECRI Institute. Clinical Evidence Assessment. NEOX Flo wound matrix (Amniox Medical, Inc.) for treating chronic wounds. <https://ecri.org>. Published December 4, 2015. Updated August 27, 2021.
28. ECRI Institute. Clinical Evidence Assessment. NeuraGen 3D nerve guide (Integra LifeSciences) for repairing nerve gap injuries. <https://ecri.org>. Published April 28, 2022.
29. ECRI Institute. Clinical Evidence Assessment. NovoSorb biodegradable temporizing matrix (PolyNovo Ltd.) for managing wounds. <https://ecri.org>. Published September 1, 2019. Updated November 2, 2021.
30. ECRI Institute. Clinical Evidence Assessment. NovoSorb biodegradable temporizing matrix (PolyNovo Ltd.) for treating full-thickness wounds. <https://ecri.org>. Published May 4, 2023.
31. ECRI Institute. Clinical Evidence Assessment. NuShield placental allograft (Organogenesis, Inc.) for treating burns. <https://ecri.org>. Published November 29, 2021.
32. ECRI Institute. Clinical Evidence Assessment. Oasis Wound Matrix (Smith & Nephew, Inc.) for treating burns. <https://ecri.org>. Published July 1, 2023.
33. ECRI Institute. Clinical Evidence Assessment. Omega3 wound matrix (Kerecis) for treating burns. <https://ecri.org>. Published February 23, 2024.
34. ECRI Institute. Clinical Evidence Assessment. Omega3 wound matrix (Kerecis) for treating chronic wounds. <https://ecri.org>. Published May 1, 2019. Updated April 1, 2023.
35. ECRI Institute. Clinical Evidence Assessment. Overview of flowable matrices for treating chronic and acute wounds. <https://ecri.org>. Published September 1, 2022.
36. ECRI Institute. Clinical Evidence Assessment. Overview of selected human amniotic membranes for treating chronic wounds. <https://ecri.org>. Published May 1, 2022.
37. ECRI Institute. Clinical Evidence Assessment. OviTex PRS reinforced tissue matrix (TELA Bio) for breast reconstruction. <https://ecri.org>. Published December 13, 2021.

38. ECRI Institute. Clinical Evidence Assessment. OviTex reinforced bioscaffolds (Tela Bio, Inc.) for hernia repair. <https://ecri.org>. Published December 16, 2021.
39. ECRI Institute. Clinical Evidence Assessment. ProLayer acellular dermal matrix (Stryker Corp.) for breast reconstruction. <https://ecri.org>. Published March 4, 2021.
40. ECRI Institute. Clinical Evidence Assessment. PuraPly AM antimicrobial wound matrix (Organogenesis, Inc.) for treating chronic wounds. <https://ecri.org>. Published November 7, 2018. Updated April 29, 2022.
41. ECRI Institute. Clinical Evidence Assessment. Restrata resorbable wound matrix (Acera Surgical) for treating acute and surgical wounds. <https://ecri.org>. Published March 22, 2024.
42. ECRI Institute. Clinical Evidence Assessment. Restrata resorbable wound matrix (Acera Surgical) for treating complex and chronic wounds. <https://ecri.org>. Published March 22, 2024.
43. ECRI Institute. Clinical Evidence Assessment. Revita placental allograft (StimLabs, LLC) for treating diabetic foot ulcers. <https://ecri.org>. Published February 1, 2022.
44. ECRI Institute. Clinical Evidence Assessment. SimpliDerm (Aziyo Biologics, Inc.) for breast reconstruction. <https://ecri.org>. Published June 14, 2022.
45. ECRI Institute. Clinical Evidence Assessment. Skin substitutes for treating diabetic foot ulcers in patients aged 65 years or older. <https://ecri.org>. Published January 25, 2021.
46. ECRI Institute. Clinical Evidence Assessment. Skin substitutes for treating pressure injuries in patients aged 65 years or older. <https://ecri.org>. Published October 29, 2024.
47. ECRI Institute. Clinical Evidence Assessment. Standard-of-care practices for managing diabetic foot ulcers. <https://ecri.org>. Published January 28, 2020. Updated December 31, 2021.
48. ECRI Institute. Clinical Evidence Assessment. StrataGraft allogeneic cellularized scaffold (Mallinckrodt Pharmaceuticals) for treating thermal burns. <https://ecri.org>. Published February 6, 2022.
49. ECRI Institute. Clinical Evidence Assessment. Strattice reconstructive tissue matrix (Abbvie, Inc.) for hernia repair. <https://ecri.org>. Published October 29, 2024.
50. ECRI Institute. Clinical Evidence Assessment. Stravix cryopreserved placental tissue (Osiris Therapeutics, Inc.) for treating surgical wounds. <https://ecri.org>. Published July 8, 2021.
51. ECRI Institute. Clinical Evidence Assessment. Suprathel skin substitute (PolyMedics Innovations GmbH) for treating burns. <https://ecri.org>. Published April 25, 2023.
52. ECRI Institute. Clinical Evidence Assessment. Suprathel skin substitute (PolyMedics Innovations GmbH) for treating donor site wounds. <https://ecri.org>. Published February 22, 2021.

53. ECRI Institute. Clinical Evidence Assessment. SurgiMend collagen matrix (Integra LifeSciences Corp.) for breast reconstruction. <https://ecri.org>. Published November 14, 2019. Updated May 4, 2021.
54. ECRI Institute. Clinical Evidence Assessment. Synthetic versus biologic mesh for breast reconstructive surgery. <https://ecri.org>. Published October 30, 2015. Updated November 11, 2024.
55. ECRI Institute. Clinical Evidence Assessment. TheraGenesis bilayer wound matrix (Gunze International USA, Inc.) for treating partial- and full-thickness wounds. <https://ecri.org>. Published February 22, 2023.
56. ECRI Institute. Hotline Response. Skin substitutes for managing pilonidal disease excision wounds. <https://ecri.org>. Published March 31, 2020.
57. ECRI Institute. Hotline Response. Synthetic versus biologic mesh for abdominal wall reconstructive surgery. <https://ecri.org>. Published October 15, 2015. Updated November 13, 2019.
58. ECRI Institute. Product Brief. AlloMax surgical graft (C.R. Bard, Inc./Davol, Inc.) for reconstructive surgery. <https://ecri.org>. Published October 9, 2015. Updated July 25, 2016.
59. ECRI Institute. Product Brief. AlloPatch HD acellular dermal matrix (Musculoskeletal Transplant Foundation) for repairing rotator cuff tears. <https://ecri.org>. Published October 23, 2017.
60. ECRI Institute. Product Brief. AmnioFix amnion/chorion membrane allograft (MiMedx) for treating surgical wounds. <https://ecri.org>. Published April 14, 2015. Updated May 10, 2019.
61. ECRI Institute. Product Brief. Avance nerve graft (AxoGen, Inc.) for repairing nerve gap injuries. <https://ecri.org>. Published March 14, 2012. Updated January 27, 2020.
62. ECRI Institute. Product Brief. Biodesign dural graft (Cook Medical) for repairing dural tears. <https://ecri.org>. Published August 26, 2015.
63. ECRI Institute. Product Brief. Biodesign hernia graft (Cook Biotech, Inc.) for reconstructive surgery. <https://ecri.org>. Published July 20, 2016.
64. ECRI Institute. Product Brief. Biodesign nipple reconstruction cylinder (Cook Medical) for plastic surgery. <https://ecri.org>. Published April 5, 2018.
65. ECRI Institute. Product Brief. Biodesign otologic repair graft (Cook Medical) for tympanic reconstruction. <https://ecri.org>. Published January 22, 2018.
66. ECRI Institute. Product Brief. BioDFactor viable tissue matrix (Integra LifeSciences) for treating surgical and chronic wounds. <https://ecri.org>. Published September 24, 2018.
67. ECRI Institute. Product Brief. CopiOs pericardium membrane (Zimmer Dental, Inc.) for use during oral surgery. <https://ecri.org>. Published February 6, 2017.

68. ECRI Institute. Product Brief. Cytal wound matrix (ACell, Inc.) for treating acute and chronic wounds. <https://ecri.org>. Published October 23, 2017. Updated March 15, 2019.
69. ECRI Institute. Product Brief. Epicord umbilical cord allograft (MiMedx) for treating diabetic foot ulcers. <https://ecri.org>. Published February 6, 2020.
70. ECRI Institute. Product Brief. EpiFix amnion/chorion membrane allograft (MiMedx) for treating chronic wounds. <https://ecri.org>. Published September 10, 2018. Updated December 2, 2019.
71. ECRI Institute. Product Brief. Gentrix surgical matrix (ACell, Inc.) for reinforcing soft tissue. <https://ecri.org>. Published June 30, 2018.
72. ECRI Institute. Product Brief. GraftJacket Regenerative Tissue Matrix (Wright Medical Technology) to augment tendon and ligament repair. <https://ecri.org>. Published April 7, 2004. Updated February 12, 2018.
73. ECRI Institute. Product Brief. Helicoll (EnColl, Corp.) type-1 collagen-based sterile dressing for treating burns and wounds. <https://ecri.org>. Published August 1, 2014.
74. ECRI Institute. Product Brief. Integra flowable wound matrix (Integra LifeSciences Corp.) for treating deep soft-tissue or tunneling wounds. <https://ecri.org>. Published February 20, 2017.
75. ECRI Institute. Product Brief. Integra template and matrix wound skin substitutes (Integra LifeSciences Corp.) for treating chronic wounds. <https://ecri.org>. Published April 1, 2018.
76. ECRI Institute. Product Brief. MatriStem MicroMatrix (ACell, Inc.) for treating surgical and chronic wounds. <https://ecri.org>. Published August 28, 2018.
77. ECRI Institute. Product Brief. NuShield placental allograft (Nutech Medical) for use in chronic and surgical wounds. <https://ecri.org>. Published September 15, 2015.
78. ECRI Institute. Product Brief. Oasis wound matrix (Smith & Nephew, Inc.) for treating surgical and chronic wounds. <https://ecri.org>. Published April 7, 2004. Updated July 25, 2016.
79. ECRI Institute. Product Brief. Permacol surgical implant (Medtronic plc) for repairing hernias and abdominal wall defects. <https://ecri.org>. Published July 25, 2016.
80. ECRI Institute. Product Brief. PriMatrix dermal repair scaffold (Integra LifeSciences Corp.) for treating chronic wounds. <https://ecri.org>. Published July 25, 2016. Updated October 31, 2019.
81. ECRI Institute. Product Brief. Promogran Prisma Matrix (Acelity L.P., Inc.) for promoting surgical wound healing. <https://ecri.org>. Published August 22, 2018.
82. ECRI Institute. Product Brief. Strattice reconstructive tissue matrix (Allergan plc) for breast reconstruction. <https://ecri.org>. Published February 3, 2012. Updated November 25, 2019.

83. ECRI Institute. Product Brief. Surgimend collagen matrix (Integra LifeSciences Corp.) for reconstructive surgery. <https://ecri.org>. Published July 5, 2016.
84. ECRI Institute. Product Brief. TheraSkin human skin allograft (Solsys Medical, LLC) for treating surgical and chronic wounds. <https://ecri.org>. Published October 5, 2018. Updated March 1, 2019.
85. ECRI Institute. Product Brief. XCM biologic tissue matrix (Ethicon US, LLC/DePuy Synthes) for reconstructive surgery. <https://ecri.org>. Published November 4, 2015. Updated July 25, 2016.
86. ECRI Institute. Product Brief. XenMatrix surgical grafts (C.R. Bard, Inc.) for hernia repair. <https://ecri.org>. Published December 5, 2019.
87. ECRI Institute. Product Brief. XenMatrix surgical grafts (C.R. Bard, Inc./Davol, Inc.) for reconstructive surgery. <https://ecri.org>. Published October 30, 2015. Updated July 25, 2016.
88. Hayes, Inc. Clinical Research Response. SimpliDerm acellular dermal matrix (Elutia). <https://evidence.hayesinc.com>. Published December 8, 2023.
89. Hayes, Inc. Evidence Analysis Research Brief. AlloDerm Regenerative Tissue Matrix (AbbVie Inc.) for head and neck procedures. <https://evidence.hayesinc.com>. Published July 13, 2023.
90. Hayes, Inc. Evidence Analysis Research Brief. AmnioBind placental membrane allograft (Pipeline Healthcare Solutions) for wound management. <https://evidence.hayesinc.com>. Published December 29, 2023.
91. Hayes, Inc. Evidence Analysis Research Brief. Apis wound dressing (SweetBio Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 3, 2023.
92. Hayes, Inc. Evidence Analysis Research Brief. Artacent Flex (Tides Medical) for treatment of wounds. <https://evidence.hayesinc.com>. Published December 29, 2023.
93. Hayes, Inc. Evidence Analysis Research Brief. ArthroFLEX decellularized dermal allograft (Arthrex, Inc.) for anterior cruciate ligament repair or reconstruction. <https://evidence.hayesinc.com>. Published August 3, 2023.
94. Hayes, Inc. Evidence Analysis Research Brief. bio-ConneKt wound matrix (MLM Biologics Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published January 20, 2023.
95. Hayes, Inc. Evidence Analysis Research Brief. carePatch (Extremity Care) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 12, 2024.
96. Hayes, Inc. Evidence Analysis Research Brief. Celera patch (Nvision Biomedical Technologies Inc.) for treatment of wounds or burns. <https://evidence.hayesinc.com>. Published December 5, 2023.
97. Hayes, Inc. Evidence Analysis Research Brief. Cygnus Matrix (Vivex Biologics) for wound management. <https://evidence.hayesinc.com>. Published March 6, 2023.

98. Hayes, Inc. Evidence Analysis Research Brief. Dernaspan (Biomet Orthopedics) for management of musculoskeletal indications. <https://evidence.hayesinc.com>. Published September 12, 2023.
99. Hayes, Inc. Evidence Analysis Research Brief. Enverse (StimLabs LLC) for treatment of wounds. <https://evidence.hayesinc.com>. Published July 25, 2023.
100. Hayes, Inc. Evidence Analysis Research Brief. FlowerPatch (Conventus Flower Orthopedics) for treatment of wounds. <https://evidence.hayesinc.com>. Published January 18, 2024.
101. Hayes, Inc. Evidence Analysis Research Brief. Human Health Factor 10 amniotic patch (Wolver & Poole Distribution LLC) for wound management. <https://evidence.hayesinc.com>. Published January 29, 2024.
102. Hayes, Inc. Evidence Analysis Research Brief. Impax Dual Layer amniotic graft (Legacy Medical Consultants) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 8, 2024.
103. Hayes, Inc. Evidence Analysis Research Brief. InnovaMatrix AC (Triad Life Sciences Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published January 20, 2023.
104. Hayes, Inc. Evidence Analysis Research Brief. InnovaMatrix FS (Triad Life Sciences Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published July 25, 2023.
105. Hayes, Inc. Evidence Analysis Research Brief. InteguPly (PuraGraft) for management of musculoskeletal indications. <https://evidence.hayesinc.com>. Published September 29, 2023.
106. Hayes, Inc. Evidence Analysis Research Brief. MemoDerm (Stryker) for management of musculoskeletal indications. <https://evidence.hayesinc.com>. Published September 19, 2023.
107. Hayes, Inc. Evidence Analysis Research Brief. Microlyte Matrix (Imbed Biosciences) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 20, 2023.
108. Hayes, Inc. Evidence Analysis Research Brief. MicroMatrix (ACell Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 25, 2022.
109. Hayes, Inc. Evidence Analysis Research Brief. Mirragen Advanced Wound Matrix (ETS Wound Care) for management of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published May 2, 2022.
110. Hayes, Inc. Evidence Analysis Research Brief. MLG-Complete (Samaritan Biologics) for treatment of wounds. <https://evidence.hayesinc.com>. Published July 27, 2023.
111. Hayes, Inc. Evidence Analysis Research Brief. NuShield placental allograft for the management of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published March 17, 2022.
112. Hayes, Inc. Evidence Analysis Research Brief. Omeza Collagen Matrix (Omeza) for treatment of wounds. <https://evidence.hayesinc.com>. Published December 1, 2023.

113. Hayes, Inc. Evidence Analysis Research Brief. PermeaDerm products (Stedical Scientific) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 1, 2024.
114. Hayes, Inc. Evidence Analysis Research Brief. Phoenix Wound Matrix (RenovoDerm) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 1, 2024.
115. Hayes, Inc. Evidence Analysis Research Brief. ProMatrX ACF (Amino Technology LLC) for treatment of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published January 4, 2024.
116. Hayes, Inc. Evidence Analysis Research Brief. Release (StimLabs LLC) for treatment of wounds. <https://evidence.hayesinc.com>. Published April 28, 2023.
117. Hayes, Inc. Evidence Analysis Research Brief. ReStrata (Acera Surgical Inc.) for wound management. <https://evidence.hayesinc.com>. Published February 3, 2023.
118. Hayes, Inc. Evidence Analysis Research Brief. Signature APatch (Signature Biologics) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 26, 2024.
119. Hayes, Inc. Evidence Analysis Research Brief. Skin substitutes for treatment of acute wounds. <https://evidence.hayesinc.com>. Published January 31, 2024.
120. Hayes, Inc. Evidence Analysis Research Brief. Supra SDRM (PolyMedics Innovations Inc.). <https://evidence.hayesinc.com>. Published July 25, 2023.
121. Hayes, Inc. Evidence Analysis Research Brief. Suprathel (PolyMedics Innovations Inc.) for wound management. <https://evidence.hayesinc.com>. Published August 22, 2023.
122. Hayes, Inc. Evidence Analysis Research Brief. SurgiMend (Integra Life Sciences) for postmastectomy breast reconstruction. <https://evidence.hayesinc.com>. Published March 24, 2023.
123. Hayes, Inc. Evidence Analysis Research Brief. SurGraft TL (Surgenex LLC) for treatment of wounds. <https://evidence.hayesinc.com>. Published February 21, 2024.
124. Hayes, Inc. Evidence Analysis Research Brief. Symphony (Aroa Biosurgery Ltd.) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 21, 2023.
125. Hayes, Inc. Evidence Analysis Research Brief. TheraGenesis (Bioventus LLC) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 21, 2023.
126. Hayes, Inc. Evidence Analysis Research Brief. Vendaje (BioStem Technologies) for wound management. <https://evidence.hayesinc.com>. Published March 14, 2023.
127. Hayes, Inc. Evidence Analysis Research Brief. Vim amniotic membrane (Cook Biotech) for treatment of surgical and nonsurgical wounds. <https://evidence.hayesinc.com>. Published February 13, 2023.

128. Hayes, Inc. Evidence Analysis Research Brief. XCelliStem wound powder (Stemsys) for treatment of wounds. <https://evidence.hayesinc.com>. Published January 19, 2023.
129. Hayes, Inc. Evidence Analysis Research Brief. Zenith amniotic membrane (Legacy Medical Consultants) for wound management. <https://evidence.hayesinc.com>. Published March 6, 2023.
130. Hayes, Inc. Evolving Evidence Review. Kerecis Omega3 wound (Kerecis) fish skin grafts for management of burns. <https://evidence.hayesinc.com>. Published February 22, 2024.
131. Hayes, Inc. Evolving Evidence Review. Kerecis Omega3 wound (Kerecis) fish skin grafts for the management of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published February 22, 2024.
132. Hayes, Inc. Evolving Evidence Review. NovoSorb biodegradable temporizing matrix (BTM) (PolyNovo Pty Ltd.) for treatment of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published January 25, 2024. Updated October 18, 2024.
133. Hayes, Inc. Evolving Evidence Review. PuraPly AM antimicrobial wound matrix (Organogenesis) for treatment of wounds. <https://evidence.hayesinc.com>. Published December 12, 2022. Updated December 18, 2024.
134. Hayes, Inc. Health Technology Assessment. Acellular skin substitutes for chronic foot ulcers in adults with diabetes mellitus. <https://evidence.hayesinc.com>. Published May 6, 2020. Updated May 10, 2023.
135. Hayes, Inc. Health Technology Assessment. Amniotic allografts for tendon and ligament injuries. <https://evidence.hayesinc.com>. Published September 16, 2020. Updated August 29, 2023.
136. Hayes, Inc. Health Technology Assessment. Cellular skin substitutes for chronic foot ulcers in adults with diabetes mellitus. <https://evidence.hayesinc.com>. Published March 26, 2020. Updated April 24, 2023.
137. Hayes, Inc. Health Technology Assessment. Grafix cryopreserved placental membrane (Osiris Technologies Inc.) for treatment of chronic foot ulcers in patients with diabetes mellitus. <https://evidence.hayesinc.com>. Published September 3, 2019. Updated October 25, 2022.
138. Hayes, Inc. Health Technology Assessment. Processed nerve allografts with the Avance Nerve Graft (Axogen Corporation) for peripheral nerve discontinuities. <https://evidence.hayesinc.com>. Published March 2, 2020. Updated May 10, 2023.
139. Hayes, Inc. Health Technology Assessment. Skin substitutes for venous leg ulcers in adults. <https://evidence.hayesinc.com>. Published July 23, 2020. Updated July 11, 2023.
140. Hayes, Inc. Health Technology Brief. FlexHD acellular dermis (Musculoskeletal Transplant Foundation) for hernia repair. <https://evidence.hayesinc.com>. Published August 8, 2012. Updated June 30, 2014.

141. Hayes, Inc. Health Technology Brief. Oasis wound matrix (Cook Biotech Inc.) for lower extremity ulcers. <https://evidence.hayesinc.com>. Published December 31, 2012. Updated December 12, 2014.
142. Hayes, Inc. Health Technology Brief. Surgisis AFP anal fistula plug (a.k.a. SIS Fistula Plug) (Cook Biotech Inc.) for repair of anal fistulas. <https://evidence.hayesinc.com>. Published April 7, 2008. Updated April 9, 2010.
143. Hayes, Inc. Medical Technology Directory. Comparative effectiveness review of biologic mesh for hernia repair: a review of reviews. <https://evidence.hayesinc.com>. Published March 16, 2018. Updated March 1, 2022.
144. Hayes, Inc. Medical Technology Directory. Comparative effectiveness review of human acellular dermal matrix for breast reconstruction. <https://evidence.hayesinc.com>. Published January 28, 2019. Updated February 28, 2022.
145. Hayes, Inc. Medical Technology Directory. Synthetic tissue for dural repair. <https://evidence.hayesinc.com>. Published May 14, 2015. Updated June 11, 2019.
146. National Pressure Injury Advisory Panel (NPIAP). Clinical Practice Guideline. Prevention and treatment of pressure ulcers/injuries: quick reference guide. <https://npiap.com>. Published 2009. Updated 2019.
147. Society for Vascular Surgery (SVS). Clinical Practice Guidelines (ARCHIVED) of the Society for Vascular Surgery and the American Venous Forum. Management of venous leg ulcers. <https://jvascsurg.org>. Published August 2014.
148. UpToDate, Inc. Basic principles of wound healing. <https://uptodate.com>. Updated December 2024.
149. UpToDate, Inc. Implant-based breast reconstruction and augmentation. <https://uptodate.com>. Updated December 2024.
150. UpToDate, Inc. Management of diabetic foot ulcers. <https://uptodate.com>. Updated December 2024.
151. UpToDate, Inc. Management of ventral hernias. <https://uptodate.com>. Updated December 2024.
152. UpToDate, Inc. Operative management of anorectal fistulas. <https://uptodate.com>. Updated December 2024.
153. UpToDate, Inc. Overview of surgical procedures used in the management of burn injuries. <https://uptodate.com>. Updated December 2024.
154. UpToDate, Inc. Overview of treatment of chronic wounds. <https://uptodate.com>. Updated December 2024.
155. UpToDate, Inc. Principles of acute wound management. <https://uptodate.com>. Updated December 2024.

156. UpToDate, Inc. Skin substitutes. <https://uptodate.com>. Updated December 2024.
157. UpToDate, Inc. Topical agents and dressings for local burn wound care. <https://uptodate.com>. Updated December 2024.
158. UpToDate, Inc. Treatment of superficial burns requiring hospital admission. <https://uptodate.com>. Updated December 2024.
159. US Government Publishing Office. Electronic code of federal regulations: part 1271 – human cells, tissues, and cellular and tissue-based products. <https://ecfr.gov>. Published January 19, 2001. Updated November 24, 2004.

Appendix

Standard wound therapy based on the specific type of wound includes:

- Appropriate offloading^{47,150}; **AND**
- Assessment of an individual's vascular status and correction of any amenable vascular problems for arterial and/or venous ulcers^{150,154}; **AND**
- Comprehensive patient assessment (history, exam, Ankle-Brachial Index [ABI]) and diagnostic tests as indicated) and implemented treatment plan¹⁵⁴; **AND**
- Compression garments/dressings have been consistently applied for venous ulcers^{150,154}; **AND**
- Frequent repositioning of an individual with pressure injuries (usually every 2 hours)¹⁵⁴; **AND**
- Improvement of glucose control^{150,154}; **AND**
- Individual with venous leg ulcer (VLU) - assessment of clinical history (prior ulcers, thrombosis risks), physical exam (edema, skin changes), ABI, diagnostic testing to verify superficial or deep venous reflux, perforator incompetence, and chronic (or acute) venous thrombosis¹⁵⁴; **AND**
- Maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings (eg, alginate, films, foams, hydrocolloid, hydrogels that provide a moist wound environment)^{47,154,155}; **AND**
- Necessary treatment to resolve any infection that may be present (eg, antibiotics, debridement of devitalized tissue, surgical management of osteomyelitis)^{47,150,154,155}

Change Summary

01/01/2025 New Policy.

02/04/2025 Update, Coverage Change. Updated Coding Information